,Drug_1,drug2,Level_of_interaction,Quality_of_interaction,Summary,Description
0,Obeticholic acid,Abacavir,No Interaction Expected,NA,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Abacavir is metabolized by alcohol dehydrogenase and UGT, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
1,Obeticholic acid,Abiraterone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Abiraterone has multiple metabolic pathways and is an inhibitor of CYP2D6. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the abiraterone SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
2,Obeticholic acid,Acalabrutinib,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acalabrutinib is a CYP3A4 and P-gp substrate, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
3,Obeticholic acid,Acamprosate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acamprosate does not undergo significant metabolism. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
4,Obeticholic acid,Acarbose,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. After ingestion of acarbose, the majority of the active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological activity and is metabolized by intestinal enzymes and by the microbial flora. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the acarbose SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
5,Obeticholic acid,Acebutolol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acebutolol is mainly excreted in the urine as the diacetolol metabolite. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ,(See Summary)
6,Obeticholic acid,Aceclofenac,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aceclofenac is metabolized by CYP2C9. This pathway is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
7,Obeticholic acid,Acenocoumarol,Potential Weak Interaction,NA,Coadministration has not been studied. Acenocoumarol is mainly metabolized by CYP2C9 and to a lesser extent by CYP1A2 and CYP2C19. Obeticholic acid may increase the exposure of CYP1A2 substrates. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the acenocoumarol SmPC contraindicates its use in patients with severe liver impairment.,(See Summary)
8,Obeticholic acid,Acetazolamide,No Interaction Expected,NA,Coadministration has not been studied but a clinically significant interaction is unlikely. Acetazolamide is excreted unchanged in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the acetazolamide SmPC contraindicates its use in patients with hepatic cirrhosis.,(See Summary)
9,Obeticholic acid,Aciclovir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aciclovir is eliminated primarily unchanged in the urine via active renal tubular secretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
10,Obeticholic acid,Acitretin,Potential Weak Interaction,NA,"Coadministration has not been studied. Acitretin undergoes isomerisation and glucuronidation. Obeticholic acid does not interact with these pathways, but acitretin is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
11,Obeticholic acid,Activated charcoal,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
12,Obeticholic acid,Adefovir,Potential Weak Interaction,NA,"Coadministration has not been studied. Adefovir is eliminated renally via glomerular filtration and active renal secretion by OAT1, which are not affected by obeticholic acid; however, adefovir is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
13,Obeticholic acid,Agomelatine,Potential Weak Interaction,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolized predominantly via CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. [Note: agomelatine is contraindicated in hepatic impairment as increases in the exposure of up to 140-times have been seen in cirrhotic patients.],(See Summary)
14,Obeticholic acid,Albendazole,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Albendazole is metabolized by CYP3A4 and by the flavin-containing monooxygenase system, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
15,Obeticholic acid,Albiglutide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Albiglutide is a protein for which the expected metabolic pathway is degradation to small peptides and individual amino acids by ubiquitous proteolytic enzymes. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces",(See Summary)
16,Obeticholic acid,Alemtuzumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alemtuzumab is a protein for which the expected metabolic pathway is degradation to small peptides and individual amino acids by widely distributed proteolytic enzymes.,(See Summary)
17,Obeticholic acid,Alendronic acid,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is no evidence in humans or animals that alendronic acid undergoes metabolism. However, if taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product. [Note: this interaction is not specific for obeticholic acid, but for any medication taken with alendronic acid.]",(See Summary)
18,Obeticholic acid,Alfentanil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfentanil undergoes extensive CYP3A4 metabolism. This pathway is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
19,Obeticholic acid,Alfuzosin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfuzosin is metabolized mainly by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
20,Obeticholic acid,Aliskiren,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolized and is mainly excreted unchanged in faeces. P-glycoprotein is a major determinant of aliskiren bioavailability, but this is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
21,Obeticholic acid,Allopurinol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: the European SmPC and US Prescribing Information for allopurinol recommend a reduced dose in hepatic impairment.],(See Summary)
22,Obeticholic acid,Almotriptan,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Almotriptan is partly eliminated unchanged in the urine and partly metabolized (mainly via monoamine oxidase- and to a lesser extent by CYP3A4, CYP2D6, and flavin monooxygenase). Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the almotriptan SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
23,Obeticholic acid,Aloe vera,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aloe vera is only a weak inhibitor of CYPs in vitro and therefore is unlikely to cause clinically significant interactions. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
24,Obeticholic acid,Alogliptin ,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin does not undergo extensive metabolism and is excreted mainly unchanged in the urine and metabolism by CYPs is minimal. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
25,Obeticholic acid,Alprazolam,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alprazolam is mainly metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the alprazolam SmPC contraindicates its use in patients with severe liver impairment.",(See Summary)
26,Obeticholic acid,Aluminium hydroxide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
27,Obeticholic acid,Alverine citrate,No Interaction Expected,NA,"Coadministration has not been studied but based on the limited understanding of metabolism and clearance a clinically significant interaction is unlikely. However, as alverine citrate affects gastric motility, an effect on the absorption of obeticholic acid cannot be ruled out. Doses of obeticholic acid and alverine should be separated by 4 hours if possible. [Note: this interaction is not specific for obeticholic acid, but for any medication taken with alverine citrate.]",(See Summary)
28,Obeticholic acid,Amantadine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amantadine is largely excreted renally via glomerular filtration and active secretion, but the transporters that mediate this have not been well described. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
29,Obeticholic acid,Ambrisentan,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ambrisentan is mainly glucuronidated by UGT1A9, UGT2B7, and UGT1A3 and is metabolized to a lesser extent by CYP3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
30,Obeticholic acid,Amikacin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amikacin is eliminated renally by glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
31,Obeticholic acid,Amiloride,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiloride is eliminated unchanged by the kidney and in vitro data indicate that it is a substrate of OCT. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
32,Obeticholic acid,Amiodarone,Potential Weak Interaction,NA,"Coadministration has not been studied. Amiodarone is metabolized mainly by CYP3A4 and by CYP2C8, which are not affected by obeticholic acid. However, amiodarone is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
33,Obeticholic acid,Amisulpride,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolized and is primarily eliminated renally. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
34,Obeticholic acid,Amitriptyline,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amitriptyline is metabolized predominantly by CYP2D6 and CYP2C19, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
35,Obeticholic acid,Amlodipine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amlodipine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
36,Obeticholic acid,Amobarbital,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amobarbital undergoes CYP-mediated metabolism but this is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
37,Obeticholic acid,Amodiaquine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amodiaquine is mainly metabolized by CYP2C8 to N-desethylamodiaquine, an active metabolite but less potent than the parent compound. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
38,Obeticholic acid,Amoxicillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly eliminated unchanged in the kidney and in vitro data indicate that it is a substrate of OAT3. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
39,Obeticholic acid,Amphetamine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amphetamine is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
40,Obeticholic acid,Amphotericin B,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amphotericin B is eliminated unchanged via urinary and biliary excretion (biliary excretion is lower with lipid-formulated amphotericin). Amphotericin B is a weak inhibitor of BSEP in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms, although the clinical relevance of this is unknown. Consider monitoring serum transaminases and bilirubin.",(See Summary)
41,Obeticholic acid,Ampicillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
42,Obeticholic acid,Anagrelide,Potential Weak Interaction,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anagrelide is primarily metabolized by CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: anagrelide is contraindicated in the SmPC in cases of moderate-severe hepatic impairment.,(See Summary)
43,Obeticholic acid,Anastrozole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anastrozole is mainly oxidized to hydroxyanastrozole by CYP3A4 (major) and glucuronidated by UGT1A4. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
44,Obeticholic acid,Anidulafungin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anidulafungin is not metabolized hepatically but undergoes chemical degradation at physiological temperature. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
45,Obeticholic acid,Antacids,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
46,Obeticholic acid,Apixaban,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Apixaban is metabolized by CYP3A4 and to a lesser extent by CYP1A2, CYP2C8, CYP2C9, and CYP2C19. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
47,Obeticholic acid,Aprepitant,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aprepitant is mainly metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C19. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
48,Obeticholic acid,Aripiprazole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aripiprazole is metabolized by multiple pathways involving CYP2D6 and CYP3A4 enzymes. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
49,Obeticholic acid,Artemether,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Artemether is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
50,Obeticholic acid,Artemisinin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Artemisinins undergo rapid metabolism via several CYP450 (CYPs 3A4, 2A6, and 2B6). The active metabolite (dihydroartemisinin, which has greater potency than the parent drug) is further metabolized via UGTs 1A9 and 2B7 and has been shown to induce CYP3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
51,Obeticholic acid,Artesunate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydroartemisinin (the active metabolite of artesunate) is metabolized via UGTs 1A9 and 2B7 and has been shown to induce CYP3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
52,Obeticholic acid,Ascorbic acid (Vitamin C),No Interaction Expected,NA,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely.",(See Summary)
53,Obeticholic acid,Asenapine,Potential Weak Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (mainly CYP1A2, with minor contributions from CYP3A4 and CYP2D6). Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: The asenapine SmPC does not recommend prescribing in severe hepatic impairment as asenapine can prolong QT. ",(See Summary)
54,Obeticholic acid,Aspirin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to salicylic acid and then further metabolized mainly by glucuronidation (by several UGT, major UGT1A6). These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
55,Obeticholic acid,Astemizole,Potential Weak Interaction,NA,"Coadministration has not been studied. Astemizole is metabolized by CYPs 2D6, 2J2, and 3A4, which are not affected by obeticholic acid. However, astemizole is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin.",(See Summary)
56,Obeticholic acid,Atazanavir alone,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Atazanavir is metabolized by CYP3A4. Obeticholic acid does not interact with this pathway; however atazanavir is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: the atazanavir SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
57,Obeticholic acid,Atazanavir/cobicistat,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Atazanavir is metabolized by CYP3A4. Cobicistat is primarily metabolized by CYP3A4 with a minor contribution from CYP2D6. Obeticholic acid does not interact with these pathways; however atazanavir is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: the atazanavir/cobicistat SmPC contraindicates its use in patients with moderate to severe hepatic impairment.",(See Summary)
58,Obeticholic acid,Atazanavir + ritonavir,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Atazanavir/ritonavir is metabolized by CYP3A4, which is not affected by obeticholic acid; however, atazanavir and ritonavir are BSEP inhibitors. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: the atazanavir SmPC contraindicates atazanavir/ritonavir use in patients with moderate to severe hepatic impairment.",(See Summary)
59,Obeticholic acid,Atenolol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atenolol is mainly eliminated unchanged in the kidney, predominantly by glomerular filtration with some involvement of OAT1, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: atenolol has been associated rarely with hepatic toxicity including intrahepatic cholestasis.",(See Summary)
60,Obeticholic acid,Atomoxetine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the European SmPC for atomoxetine recommends a reduced dose in hepatic impairment.",(See Summary)
61,Obeticholic acid,Atorvastatin,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Atorvastatin is metabolized CYP3A4 and is a substrate of OATP1B1, OATP1B3, MDR1 and BCRP, none of which are affected by obeticholic acid. However, atorvastatin is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
62,Obeticholic acid,Atovaquone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant is unlikely as atovaquone is mainly eliminated unchanged in the faeces. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
63,Obeticholic acid,Atropine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atropine metabolism has not been well described but is thought to be by oxidation and conjugation to inactive metabolites and up to 50% is excreted unchanged by the kidneys. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
64,Obeticholic acid,Avelumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avelumab is primarily metabolized through catabolic pathways and drug-drug interactions are not expected.,(See Summary)
65,Obeticholic acid,Axitinib,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Axitinib is mainly metabolized by CYP3A4 but also CYP2C19 and CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
66,Obeticholic acid,Azathioprine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azathioprine is metabolized to 6-mercaptopurine which is further inactivated by xanthine oxidase and thiopurine methyltransferase. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
67,Obeticholic acid,Azilsartan,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azilsartan is predominantly metabolized by CYP2C9, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
68,Obeticholic acid,Azithromycin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azithromycin is mainly eliminated via biliary excretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
69,Obeticholic acid,Aztreonam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aztreonam is only minimally metabolized and is eliminated mainly unchanged in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
70,Obeticholic acid,Baclofen,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Baclofen undergoes minimal metabolism in the liver and is eliminated in the urine as mainly (70-80% of the dose) as unchanged drug. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
71,Obeticholic acid,Basiliximab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Basiliximab is an immunoglobulin and no metabolic drug-drug interactions are expected. Extensive studies have been carried out with concomitant medication showing no adverse effects.,(See Summary)
72,Obeticholic acid,Beclometasone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Beclometasone is a pro-drug, which is not metabolized by CYP450 but is hydrolysed via esterase enzymes to the highly active metabolite beclometasone-17-monopropionate. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
73,Obeticholic acid,Bedaquiline,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bedaquiline is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
74,Obeticholic acid,Benazepril,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Benazepril is glucuronidated and renally cleared. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
75,Obeticholic acid,Bendroflumethiazide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is mainly eliminated by hepatic metabolism, although the exact pathway is not known. It is unlikely that CYP enzymes are involved in this process and no transporter interactions have been described. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the bendroflumethiazide SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
76,Obeticholic acid,Benralizumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Benralizumab is a humanised IgG1 monoclonal antibody that is degraded by proteolytic enzymes widely distributed in the body and not restricted to hepatic tissue.,(See Summary)
77,Obeticholic acid,Benztropine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Benztropine is primarily metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
78,Obeticholic acid,Benzylpenicillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
79,Obeticholic acid,Bepridil,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bepridil is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
80,Obeticholic acid,Betahistine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Betahistine undergoes nearly complete metabolism by monoamine oxidase. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
81,Obeticholic acid,Betamethasone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Betamethasone is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ",(See Summary)
82,Obeticholic acid,Bevacizumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bevacizumab biotransformation involves proteolytic catabolism throughout the body, including endothelial cells, and does not rely primarily on elimination through the kidneys and liver. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
83,Obeticholic acid,Bezafibrate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bezafibrate is metabolized by hydroxylation, glucuronidation, and renal elimination (~50%). [Note: the European SmPC for bezafibrate contraindicates its use in significant hepatic disease.]",(See Summary)
84,Obeticholic acid,Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bictegravir is partly metabolized by CYP3A4 and partly glucuronidated by UGT1A1; emtricitabine and tenofovir alafenamide are eliminated renally. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
85,Obeticholic acid,Bilastine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bilastine is a substrate of P-gp and OATP, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
86,Obeticholic acid,Bimatoprost,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No interactions are anticipated since although the drug is metabolized and is a BSEP inhibitor, the systemic concentrations of bimatoprost are extremely low (less than 0.2 ng/ml) following ocular dosing with bimatoprost.",(See Summary)
87,Obeticholic acid,Biperiden,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although limited human data suggest biperiden undergoes hydroxylation in the liver, there are no known or documented interactions with other drugs that have an effect on metabolism or transport.",(See Summary)
88,Obeticholic acid,Bisacodyl,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisacodyl is converted to an active metabolite by intestinal and bacterial enzymes. Absorption from the gastrointestinal tract is minimal and the small amount absorbed is excreted in the urine as the glucuronide. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
89,Obeticholic acid,Bisoprolol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolized by CYP3A4 and CYP2D6 and partly eliminated unchanged in the urine. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: the US Prescribing Information recommends an initial 2.5 mg in hepatic impairment with caution in further dose titration. The SmPC does not recommend a dose adjustment but advised clinical monitoring.],(See Summary)
90,Obeticholic acid,Black cohosh (Actaea racemosa),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction Is unlikely. Black cohosh does not appear to be a potent modulator of human drug metabolism. Standardized black cohosh supplements, when taken at recommended doses, pose little risk for herb-drug interactions. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
91,Obeticholic acid,Blinatumomab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolic pathway of blinatumomab has not been characterised. Like other protein therapeutics, blinatumomab is expected to be degraded into small peptides and amino acids via catabolic pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
92,Obeticholic acid,Bortezomib,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant is unlikely. Bortezomib is mainly metabolized by CYP3A4 and 2C19 and to a lesser extent by CYPs 1A2, 2D6, and 2C9. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
93,Obeticholic acid,Bosentan,Potential Interaction,NA,"Coadministration has not been studied. Bosentan is a substrate and inducer of CYP3A4. Obeticholic acid does not interact with these pathways; however, bosentan is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: the bosentan SmPC contraindicates its use in patients with moderate to severe hepatic impairment.",(See Summary)
94,Obeticholic acid,Bosutinib,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bosutinib is mainly metabolized by CYP3A4, which is not affected by obeticholic acid. However, the risk of hepatotoxicity may be potentially increased as both drugs can cause drug-induced liver injury. If coadministration is necessary, monitor serum transaminases and bilirubin. Note: the bosutinib SmPC contraindicates its use in patients with hepatic impairment.",(See Summary)
95,Obeticholic acid,Brentuximab vedotin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin releases the active species MMAE within the tumour cell; MMAE is a substrate of CYP3A4 and possibly CYP2D6 and a weak inhibitor of CYP3A4. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
96,Obeticholic acid,Brinzolamide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brinzolamide is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
97,Obeticholic acid,Brivudine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brivudine is an analogue of thymidine and is incorporated into viral DNA. The metabolism of brivudine is poorly described but to date, there is no evidence of CYP or transporter involvement. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
98,Obeticholic acid,Brodalumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brodalumab is degraded into small peptides.,(See Summary)
99,Obeticholic acid,Bromazepam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromazepam undergoes oxidative biotransformation. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
100,Obeticholic acid,Bromocriptine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromocriptine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
101,Obeticholic acid,Bromperidol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromperidol is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
102,Obeticholic acid,Budesonide,Potential Weak Interaction,NA,"Coadministration has not been studied. Budesonide is a substrate for CYP3A4, which is not affected by obeticholic acid; however, budesonide is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
103,Obeticholic acid,Bumetanide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Around 80% of administered bumetanide is excreted in the urine as unchanged drug. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
104,Obeticholic acid,Bupivacaine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupivacaine is metabolized by UGT1A1, CYP1A2 and CYP3A4, and amide hydrolysis. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
105,Obeticholic acid,Buprenorphine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buprenorphine is metabolized by CYP3A4 and undergoes glucuronidation, primarily via UGT1A1. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
106,Obeticholic acid,Bupropion,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is metabolized by CYP2B6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the bupropion SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
107,Obeticholic acid,Buspirone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buspirone is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
108,Obeticholic acid,Calcitonin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcitonin is metabolized primarily via proteolysis in the kidney and to date, no clinically significant interactions have been published that would be of concern.",(See Summary)
109,Obeticholic acid,Calcium carbimide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcium carbimide is a prodrug requiring catalase and hydrogen peroxide to generate the active metabolite and is an inhibitor of ALDH. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
110,Obeticholic acid,Calcium resonium,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. As calcium resonium is not absorbed.,(See Summary)
111,Obeticholic acid,Canagliflozin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Canagliflozin is metabolized by UGT1A9 and UGT2B4 and is a substrate and inhibitor of P-gp. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
112,Obeticholic acid,Candesartan,Potential Interaction,NA,"Coadministration has not been studied. Candesartan is mainly eliminated unchanged via urine and bile and is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. [Note: use of candesartan in severe hepatic impairment is contraindicated in the European SmPC; the US Prescribing Information recommends caution in moderate hepatic impairment.]",(See Summary)
113,Obeticholic acid,Cannabis,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. THC, the principal psychoactive constituent of cannabis, is metabolized mainly by CYP2C9 and to a lesser extent by CYP3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
114,Obeticholic acid,Capecitabine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capecitabine is activated by sequential enzyme reactions to fluorouracil. Dihydropyrimidine dehydrogenase plays a role in fluorouracil metabolism. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the capecitabine SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
115,Obeticholic acid,Capreomycin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capreomycin is predominantly excreted in the urine as unchanged drug. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
116,Obeticholic acid,Captopril,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Captopril is largely excreted in the urine (40-50% as unchanged drug, the rest as disulfide and other metabolites). Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
117,Obeticholic acid,Carbamazepine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carbamazepine is primarily metabolized by CYP3A4 and is a potent inducer of CYP3A4. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
118,Obeticholic acid,Carbidopa,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carbidopa is partly metabolized and partly eliminated unchanged (30% of the total urinary excretion). Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
119,Obeticholic acid,Carbimazole,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carbimazole is a pro-drug that undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole (also known as methimazole). Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the carbimazole SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
120,Obeticholic acid,Carboplatin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carboplatin is excreted primarily by renal glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
121,Obeticholic acid,Carisoprodol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carisoprodol is metabolized by CYP2C19, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
122,Obeticholic acid,Carvedilol,No Interaction Expected,NA,"Coadministration has not been studied based on metabolism and clearance a clinically significant is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4, and 2B7, with additional metabolism via CYP2D6 and to a lesser extent by CYPs 2C9 and 1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: the US Prescribing Information contraindicates carvedilol in patients with severe liver impairment and the European SmPC contraindicates it in patients with hepatic dysfunction.]",(See Summary)
123,Obeticholic acid,Caspofungin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and non-CYP mediated metabolism. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: no dose adjustment is required in patients with normal hepatic function but a dose reduction of caspofungin daily dose to 35 mg is recommended for adults with moderate hepatic impairment. There is no clinical experience in adults with severe hepatic impairment.],(See Summary)
124,Obeticholic acid,Cat's claw (Uncaria tomentosa),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cat’s claw is a CYP3A4 inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
125,Obeticholic acid,Cefaclor,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefaclor is predominantly eliminated unchanged by the kidneys. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
126,Obeticholic acid,Cefadroxil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefadroxil is not metabolized and is predominantly eliminated unchanged by the kidneys. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
127,Obeticholic acid,Cefalexin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly eliminated unchanged renally by glomerular filtration and tubular secretion via OAT1 and MATE1. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
128,Obeticholic acid,Cefazolin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion via OAT3. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
129,Obeticholic acid,Cefixime,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefixime is renally excreted predominantly by glomerular filtration, with no significant active renal tubular secretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
130,Obeticholic acid,Cefotaxime,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefotaxime is partially metabolized by non-specific esterases. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
131,Obeticholic acid,Cefradine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefradine is excreted predominantly by renal glomerular filtration, with no significant active renal tubular secretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
132,Obeticholic acid,Ceftaroline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftaroline is not metabolized by CYP enzymes and is excreted predominantly by renal glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
133,Obeticholic acid,Ceftazidime,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftazidime is excreted predominantly by renal glomerular filtration, with no significant active renal tubular secretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
134,Obeticholic acid,Ceftriaxone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftriaxone is excreted predominantly by renal glomerular filtration with minimal active renal tubular secretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
135,Obeticholic acid,Cefuroxime,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefuroxime is excreted predominantly by renal glomerular filtration, with no significant active renal tubular secretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
136,Obeticholic acid,Celecoxib,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is metabolized mainly by CYP2C9. This pathway is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: use in patients with severe liver impairment is contraindicated in the European SmPC and not recommended in the US Prescribing Information. In patients with moderate liver impairment (serum albumin 25-35 g/L, Child-Pugh Class B), celecoxib treatment should be started at half the recommended dose.]",(See Summary)
137,Obeticholic acid,Celiprolol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of celiprolol is minimal and it is mainly excreted unchanged in the urine and faeces. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
138,Obeticholic acid,Cetirizine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cetirizine is metabolized only to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
139,Obeticholic acid,Cetuximab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, cetuximab is expected to be degraded into small peptides and amino acids via catabolic pathways.",(See Summary)
140,Obeticholic acid,Chlorambucil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Very little has been described about chlorambucil metabolism in humans but CYP450 enzymes are not involved. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
141,Obeticholic acid,Chloramphenicol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chloramphenicol is predominantly metabolized mainly by UGT2B7, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
142,Obeticholic acid,Chloroquine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4, and 2D6, and is eliminated unchanged via the kidney (50%). Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the European SmPC and US Prescribing Information for chloroquine both recommend caution in impaired hepatic function.",(See Summary)
143,Obeticholic acid,Chlorothiazide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorothiazide is not metabolized and is eliminated rapidly by renal excretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
144,Obeticholic acid,Chlorphenamine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorphenamine is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
145,Obeticholic acid,Chlorpromazine,No Interaction Expected,NA,"Coadministration has not been studied, but based on metabolism and clearance pharmacokinetic interaction is unlikely. Chlorpromazine is metabolized mainly by CYP2D6, but also CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: the European SmPC for chlorpromazine advises close clinical monitoring when prescribing chlorpromazine to patients with severe hepatic dysfunction.]",(See Summary)
146,Obeticholic acid,Chlorprothixene,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorprothixene is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: although no interaction is anticipated, ECG monitoring is mandatory prior to treatment with chlorprothixene.]",(See Summary)
147,Obeticholic acid,Chlortalidone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlortalidone is largely excreted unchanged in the urine and faeces. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
148,Obeticholic acid,Ciclesonide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is hydrolyzed by esterases to an active metabolite, des-ciclesonide, which is further metabolized by CYP3A4 and to a lesser extent by CYP2D6. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
149,Obeticholic acid,Ciclosporin (Cyclosporine),Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Ciclosporin is mainly metabolized by CYP3A4, which is not affected by obeticholic acid; however, ciclosporin is a strong BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.","Avoid concomitant inhibitors of the bile salt efflux pump (BSEP) such as cyclosporine. Concomitant medications that inhibit canalicular membrane bile acid transporters such as the BSEP may exacerbate accumulation of conjugated bile salts including taurine conjugate of obeticholic acid in the liver and result in clinical symptoms. If concomitant use is deemed necessary, monitor serum transaminases and bilirubin.Ocaliva Prescribing Information, Intercept Pharmaceuticals Inc., January 2018."
150,Obeticholic acid,Cidofovir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cidofovir is eliminated renally via glomerular filtration and active renal secretion by OAT1 and OAT3. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
151,Obeticholic acid,Cilazapril,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cilazapril is rapidly converted to the active form, cilazaprilat, which is excreted unchanged in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: in patients with cirrhosis, a maximum dose of 0.5 mg/day is recommended as significant hypotension may occur.]",(See Summary)
152,Obeticholic acid,Cilostazol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cilostazol is extensively metabolized by CYP3A4 and CYP2C19 and to a limited extent by CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
153,Obeticholic acid,Cimetidine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cimetidine is eliminated primarily by renal excretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
154,Obeticholic acid,Ciprofloxacin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged through the kidneys (by glomerular filtration and tubular secretion via OAT3). Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
155,Obeticholic acid,Cisapride,Potential Weak Interaction,NA,"Coadministration has not been studied. Cisapride is metabolized mainly by CYP3A4, which is not affected by obeticholic acid; however, cisapride is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
156,Obeticholic acid,Cisatracurium,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisatracurium undergoes mainly (80% of overall elimination) spontaneous degradation in plasma and tissues at physiological pH and temperature (Hofmann elimination). Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
157,Obeticholic acid,Cisplatin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisplatin is eliminated renally via OCT2 and MATE1. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
158,Obeticholic acid,Citalopram,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Citalopram is metabolized by multiple pathways, namely CYP2C19 (38%), 2D6 (31%) and 3A4 (31%). Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
159,Obeticholic acid,Clarithromycin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clarithromycin is a substrate and inhibitor of both CYP3A4 and P-gp. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
160,Obeticholic acid,Clavulanic acid,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clavulanic acid is extensively metabolized (likely by a non-CYP mediated pathway) and excreted in the urine by glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
161,Obeticholic acid,Clevidipine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clevidipine is rapidly metabolized by hydrolysis of the ester linkage. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
162,Obeticholic acid,Clindamycin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clindamycin is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
163,Obeticholic acid,Clobazam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clobazam is metabolized primarily by CYP3A4 and to a lesser extent by CYP2C19. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the clobazam SmPC contraindicates its use in patients with severe liver impairment.,(See Summary)
164,Obeticholic acid,Clobetasol (topical),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Following topical application to most areas of normal skin, only minimal amounts of the drug reach the dermis and subsequently the systemic circulation.",(See Summary)
165,Obeticholic acid,Clobetasone (topical),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Following topical application to most areas of normal skin, only minimal amounts of the drug reach the dermis and subsequently the systemic circulation.",(See Summary)
166,Obeticholic acid,Clodronate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clodronate is not metabolized and is primarily excreted unchanged by the kidney. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
167,Obeticholic acid,Clomifene,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Studies suggest clomifene is metabolized by CYP3A4, CYP2D6, and UGTs. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
168,Obeticholic acid,Clomipramine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
169,Obeticholic acid,Clonazepam,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clonazepam is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the clonazepam SmPC contraindicates its use in patients with severe hepatic insufficiency.",(See Summary)
170,Obeticholic acid,Clonidine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% administered clonidine is excreted in the urine, mainly in the form of the unchanged parent drug (40-60% of the dose). Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
171,Obeticholic acid,Clopidogrel,Potential Weak Interaction,NA,"Coadministration has not been studied. Clopidogrel is a prodrug that is converted to its active metabolites via CYPs 3A4, 2B6, 2C19, and 1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. However, clopidogrel is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin. [Note, the European SmPC for clopidogrel contraindicates its use in severe hepatic impairment but the US Prescribing Information states no dose alteration.]",(See Summary)
172,Obeticholic acid,Clorazepate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam, which is then metabolized to oxazepam by CYP3A4. These pathways are not affected by obeticholic acid. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
173,Obeticholic acid,Clotiapine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of clotiapine has not been well characterised but is likely to involve CYP450 enzymes. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
174,Obeticholic acid,Cloxacillin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cloxacillin is metabolized to a limited extent, and the unchanged drug and metabolites are excreted via renal glomerular filtration and tubular secretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
175,Obeticholic acid,Clozapine,Potential Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Clozapine is metabolized by CYP1A2 and CYP3A4. Obeticholic acid may increase the exposure of CYP1A2 substrates. Clozapine is associated with significant toxicities, including myelosuppression, and in the absence of further data, close monitoring is recommended. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ",(See Summary)
176,Obeticholic acid,Cocaine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cocaine is metabolized by several pathways (non-CYP and CYP mediated), with metabolism to norcocaine by CYP3A4 being less than 10% of the overall metabolic clearance. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
177,Obeticholic acid,Codeine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Codeine is metabolized by CYP2D6 and CYP3A4. The analgesic effect requires the conversion of codeine to morphine via CYP2D6. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
178,Obeticholic acid,Colchicine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Colchicine is a substrate of CYP3A4 and P-gp, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the colchicine SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
179,Obeticholic acid,Colecalciferol (Vitamin D),No Interaction Expected,NA,Coadministration has not been studied but a clinically significant interaction is unlikely as colecalciferol undergoes extensive metabolism by multiple channels,(See Summary)
180,Obeticholic acid,Colestyramine,Potential Weak Interaction,NA,Coadministration has not been studied. Colestyramine is not absorbed from the digestive tract but it reduces bile acid absorption and may reduce the efficacy of obeticholic acid. Take obeticholic acid at least 4-6 hours before or 4-6 hours after colestyramine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,"Bile acid binding resins such as cholestyramine adsorb and reduce bile acid absorption and may reduce efficacy of obeticholic acid. When concomitant bile acid binding resins are administered, obeticholic acid should be taken at least 4-6 hours before or 4-6 hours after taking a bile acid binding resin, or at as great an interval as possible.Ocaliva SmPC, Intercept Pharma UK & Ireland, March 2018.For patients taking bile acid binding resins, take Ocaliva at least 4 hours before or 4 hours after taking a bile acid binding resin, or at as great an interval as possible. Bile acid binding resins such as cholestyramine adsorb and reduce bile acid absorption and may reduce the absorption, systemic exposure, and efficacy of Ocaliva.Ocaliva Prescribing Information, Intercept Pharmaceuticals Inc., January 2018."
181,Obeticholic acid,Conivaptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Conivaptan is a substrate and inhibitor of CYP3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
182,Obeticholic acid,Cyanocobalamin (Vitamin B12),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyanocobalamin undergoes enterohepatic recycling and is excreted almost entirely in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
183,Obeticholic acid,Cyclizine,No Interaction Expected,NA,"Coadministration has not been studied but based on limited data for the metabolism and clearance of cyclizine, a clinically significant interaction is unlikely. Cyclizine undergoes hepatic metabolism, which may include CYP2D6. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
184,Obeticholic acid,Cyclobenzaprine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyclobenzaprine undergoes a complex metabolic process involving glucuronidation and several CYP enzymes including CYPs 3A4 and 1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
185,Obeticholic acid,Cytisine,No Interaction Expected,NA,Coadministration has not been studied and the pharmacokinetics of cytisine is poorly described. There are no reports of drug interactions or CYP involvement. Based on limited data for metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
186,Obeticholic acid,Dabigatran,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dabigatran is not metabolized by CYP450 isoenzymes but is transported by P-gp, and is mainly cleared by glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ",(See Summary)
187,Obeticholic acid,Daclatasvir,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Daclatasvir is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
188,Obeticholic acid,Dalteparin,No Interaction Expected,NA,Coadministration has not been studied but a clinically significant interaction is unlikely. Dalteparin is excreted largely unchanged via the kidneys. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
189,Obeticholic acid,Danaparoid,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Danaparoid is renally excreted and no hepatic involvement was shown in animal studies. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
190,Obeticholic acid,Dantron,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dantron is absorbed from the small intestine and acts at the large intestine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
191,Obeticholic acid,Dapagliflozin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dapagliflozin is metabolized by UGT1A9, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
192,Obeticholic acid,Dapsone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of dapsone is largely by N-acetylation and multiple CYP enzymes have been described. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
193,Obeticholic acid,Daratumumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, daratumumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes. ",(See Summary)
194,Obeticholic acid,Darbepoetin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Darbepoetin is not hepatically metabolized and to date, no clinically significant interactions have been published that would be of concern.",(See Summary)
195,Obeticholic acid,Darunavir/cobicistat,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Darunavir is metabolized by CYP3A4. Cobicistat is primarily metabolized by CYP3A4 with a minor contribution from CYP2D6. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the darunavir SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
196,Obeticholic acid,Darunavir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (DRV/c/FTC/TAF),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Darunavir is metabolized by CYP3A4. Cobicistat is primarily metabolized by CYP3A4 with a minor contribution from CYP2D6; emtricitabine and tenofovir alafenamide are eliminated renally. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the Symtuza SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
197,Obeticholic acid,Darunavir + ritonavir,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Darunavir/ritonavir is metabolized by CYP3A4, which is not affected by obeticholic acid; however, ritonavir is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: the darunavir SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
198,Obeticholic acid,Dasatinib,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Dasatinib is a substrate and an inhibitor of cytochrome CYP3A4. Obeticholic acid does not interact with this pathway; however, dasatinib is an inhibitor of BSEP. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
199,Obeticholic acid,Deferiprone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Deferiprone is glucuronidated by UGT1A6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
200,Obeticholic acid,Delamanid,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Delamanid is primarily metabolized by albumin to DM-6705; metabolism of DM-6705 to other metabolites is thought to involve pathways mediated by CYP enzymes, including CYP3A4. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: delamanid is not recommended in patients with moderate to severe hepatic impairment.]",(See Summary)
201,Obeticholic acid,Denosumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Denosumab is not eliminated via hepatic metabolism but follows the immunoglobulin clearance pathway resulting in degradation to small peptides and individual amino acids.,(See Summary)
202,Obeticholic acid,Desipramine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desipramine is metabolized mainly by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
203,Obeticholic acid,Desloratadine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of desloratadine is poorly characterised and no clinically relevant interactions have been observed with other inhibitors of CYP enzymes. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
204,Obeticholic acid,Desmopressin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely, as desmopressin undergoes no significant metabolism.",(See Summary)
205,Obeticholic acid,Desogestrel (POP),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug that requires activation to etonogestrel. Activation to etonogestrel is by CYP2C9 (and possibly CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the Cerazette SmPC contraindicates its use in patients with severe hepatic disease.,(See Summary)
206,Obeticholic acid,Desvenlafaxine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desvenlafaxine is a metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: a maximum dose of 50 mg is recommended in moderate hepatic impairment.]",(See Summary)
207,Obeticholic acid,Dexamethasone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexamethasone is a substrate and mild inducer of CYP3A4. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
208,Obeticholic acid,Dexamfetamine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
209,Obeticholic acid,Dexketoprofen,No Interaction Expected,NA,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Dexketoprofen is mainly glucuronidated, with CYP mediated metabolism (CYP2C8/9) playing only a minor role. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: use in patients with severe hepatic impairment (Child-Pugh class C) is contraindicated in the European SmPC for dexketoprofen.]",(See Summary)
210,Obeticholic acid,Dextromethorphan,No Interaction Expected,NA,"Coadministration of 30 mg dextromethorphan with 10 mg obeticholic acid reduced dextromethorphan AUC and Cmax by 11% and 13%, respectively. This reduction is not clinically significant. Dextromethorphan is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.","No clinically relevant interactions were seen when the following drugs were administered as single doses concomitantly with Ocaliva 10 mg once daily: Dextromethorphan 30 mg (CYP2D6 substrate): 11% decrease in AUC and 12% decrease in Cmax of dextromethorphan.Ocaliva Prescribing Information, Intercept Pharmaceuticals Inc., January 2018.Coadministration of dextromethorphan (30 mg, single dose) with obeticholic acid (10 or 25 mg, once daily) was studied in 48 healthy volunteers in a crossover study. Dextromethorphan AUC and Cmax decreased by 11% and 13%, respectively, with the 10 mg dose. With the 25 mg dose of obeticholic acid, dextromethorphan AUC and Cmax decreased by 11% and 18%, respectively. Neither of these interactions is clinically significant.Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Edwards JE, Eliot L, Parkinson A, et al. Adv Ther. 2017, 34(9): 2120–2138."
211,Obeticholic acid,Dextropropoxyphene,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dextropropoxyphene is metabolized by CYP3A4. This pathway is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
212,Obeticholic acid,Diamorphine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolized by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
213,Obeticholic acid,Diazepam,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolized by CYP3A4 and CYP2C19, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the diazepam SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
214,Obeticholic acid,Diclofenac,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is a substrate of CYP2C9, CYP3A4, UGT1A9, and UGT2B7 and is an inhibitor of the renal transporter MRP4. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
215,Obeticholic acid,Didanosine,No Interaction Expected,NA,"Coadministration has not been studied but based on the metabolism and clearance a pharmacokinetic interaction is unlikely. Didanosine is phosphorylated to its active triphosphate form and the parent drug is renally excreted. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. However, didanosine has been associated with symptomatic hyperlactatemia/lactic acidosis and hepatic steatosis, non-cirrhotic portal hypertension, hepatitis, and liver failure. Coadminister with caution, as obeticholic acid has also been associated with drug-induced liver injury. Closely monitor liver function.",(See Summary)
216,Obeticholic acid,Dienogest,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dienogest is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the dienogest SmPC contraindicates its use in patients with severe hepatic disease.",(See Summary)
217,Obeticholic acid,Diflunisal,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diflunisal is an aldo-keto reductase inhibitor. This pathway is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
218,Obeticholic acid,Digoxin,No Interaction Expected,NA,"Coadministration of digoxin (0.25 mg) and obeticholic acid (10 mg) increased digoxin AUC by 1% and decreased Cmax by 3%. Digoxin is a substrate of P-gp, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.","No clinically relevant interactions were seen when the following drugs were administered as single doses concomitantly with Ocaliva 10 mg once daily: Digoxin 0.25 mg (P-gp substrate): 1% increase in AUC and 3% decrease in Cmax of digoxin.Ocaliva Prescribing Information, Intercept Pharmaceuticals Inc., January 2018.Coadministration of digoxin (0.25 mg, single dose) with obeticholic acid (10 and 25 mg, once daily) was studied in 48 healthy volunteers in a crossover trial. Digoxin AUC increased by 1% and Cmax decreased by 3% with the 10 mg dose and increased by 7% and 24% with the 25 mg dose of obeticholic acid.Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Edwards JE, Eliot L, Parkinson A, et al. Adv Ther. 2017, 34(9): 2120–2138."
219,Obeticholic acid,Dihydroartemisinin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydroartemisinin is metabolized by UGTs 1A9 and 2B7 and induces CYP3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
220,Obeticholic acid,Dihydrocodeine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine is converted to dihydromorphine (active metabolite) by CYP2D6, to dihydrocodeine-6-glucuronide by UGT2B7 (major pathway) and to nordihydrocodeine by CYP3A4. The analgesic effect appears to be primarily due to the parent compound. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
221,Obeticholic acid,Dihydroergotamine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydroergotamine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
222,Obeticholic acid,Diltiazem,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diltiazem is metabolized by CYP3A4 and CYP2D6, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
223,Obeticholic acid,Diosmin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diosmin is a naturally occurring flavonoid. Diosmin-containing products are available as dietary supplements or on prescription (in certain countries). Interaction studies suggest that diosmin may be a weak inhibitor of CYP3A4 and P-gp. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
224,Obeticholic acid,Diphenhydramine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: diphenhydramine should be used with caution in patients with moderate to severe hepatic impairment.]",(See Summary)
225,Obeticholic acid,Dipyridamole,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Dipyridamole is glucuronidated and does not appear to be metabolized by cytochrome P450s. Obeticholic acid does not interact with this pathway; however, dipyridamole is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
226,Obeticholic acid,Disopyramide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Disopyramide is primarily eliminated by the kidney. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
227,Obeticholic acid,Disulfiram,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Disulfiram is a substrate and an inhibitor of BSEP. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
228,Obeticholic acid,Dofetilide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dofetilide is eliminated in the kidney by cationic secretion and is metabolized to a small extent by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
229,Obeticholic acid,Dolutegravir,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolutegravir is primarily metabolized by UGT1A1, with some contribution from CYP3A. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
230,Obeticholic acid,Dolutegravir/rilpivirine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rilpivirine is metabolized primarily by CYP3A. Dolutegravir is primarily metabolized by UGT1A1, with some contribution from CYP3A. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
231,Obeticholic acid,Domperidone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Domperidone is metabolized by CYP3A4, CYP1A2, and CYP2E1. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the domperidone SmPC contraindicates its use in patients with moderate or severe hepatic impairment.",(See Summary)
232,Obeticholic acid,Donepezil,Potential Weak Interaction,NA,"Coadministration has not been studied. Donepezil is metabolized by CYP3A4 and CYP2D6 (minor) which are not affected by obeticholic acid; however, donepezil is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin.",(See Summary)
233,Obeticholic acid,Doravirine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doravirine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
234,Obeticholic acid,Doravirine/Lamivudine/Tenofovir-DF,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doravirine is metabolized by CYP3A4; lamivudine and tenofovir-DF are excreted renally. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
235,Obeticholic acid,Dorzolamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dorzolamide undergoes minimal metabolism and is largely excreted unchanged in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
236,Obeticholic acid,Dosulepin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dosulepin is extensively metabolized in the liver, likely by CYP2D6 (major) and CYP3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: Dosulepin should be used with caution in mild to moderate hepatic impairment and avoided in severe hepatic impairment.]",(See Summary)
237,Obeticholic acid,Doxazosin,Potential Weak Interaction,NA,"Coadministration has not been studied. Doxazosin is metabolized mainly by CYP3A4, which is not affected by obeticholic acid; however, doxazosin is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. [Note, the European SmPC does not recommend doxazosin in severe hepatic impairment; the US Prescribing Information has a caution for use in hepatic impairment.]",(See Summary)
238,Obeticholic acid,Doxepin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolized mainly by CYP2C19 to nordoxepin, an active metabolite. In addition, doxepin and nordoxepin are metabolized by CYP2D6. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: the US product label for doxepin advises a dose reduction of doxepin and monitoring in patients with hepatic impairment.]",(See Summary)
239,Obeticholic acid,Doxorubicin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxorubicin is mainly eliminated in the bile. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
240,Obeticholic acid,Doxycycline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxycycline is mainly excreted in the urine and faeces as unchanged active substance. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
241,Obeticholic acid,Doxylamine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Limited data available for doxylamine metabolism suggest the involvement of CYP2B6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
242,Obeticholic acid,Dronedarone,Potential Weak Interaction,NA,"Coadministration has not been studied. Dronedarone is primarily metabolized by CYP3A4, which is not affected by obeticholic acid. However, dronedarone is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin. Note: the dronedarone SmPC contraindicates its use in patients with severe liver impairment.",(See Summary)
243,Obeticholic acid,Droperidol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Droperidol is metabolized by CYP3A4 and CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
244,Obeticholic acid,Drospirenone (POP),Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Drospirenone is metabolized to a minor extent via CYP3A4, with little known involvement of transporters. These pathways are not affected by obeticholic acid; however, drospirenone is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
245,Obeticholic acid,Dulaglutide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dulaglutide is presumed to be degraded into its component amino acids by general protein catabolism pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
246,Obeticholic acid,Duloxetine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Duloxetine is metabolized by CYP2D6 and CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: duloxetine is contraindicated in patients with hepatic impairment as concentrations may increase due to decreased clearance of duloxetine.],(See Summary)
247,Obeticholic acid,Dupilumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dupilumab is a protein and degrades to small peptides and individual amino acids.,(See Summary)
248,Obeticholic acid,Dutasteride,Potential Weak Interaction,NA,"Coadministration has not been studied. Dutasteride is mainly metabolized by CYP3A4, which is not affected by obeticholic acid; however, dutasteride is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. [Note: the European SmPC (but not the US Prescribing Information) cautions against dutasteride use in mild to moderate hepatic impairment and contraindicates it in severe hepatic impairment.]",(See Summary)
249,Obeticholic acid,Ebastine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ebastine is metabolized by CYP450. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
250,Obeticholic acid,Echinacea,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Studies using a cocktail of probe drugs showed Echinacea inhibited CYP1A2 and intestinal CYP3A activity, and induced hepatic CYP3A activity. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
251,Obeticholic acid,Ecstasy (MDMA),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. MDMA is metabolized mainly by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
252,Obeticholic acid,Eculizumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eculizumab contains only naturally occurring amino acids and has no known active metabolites. Human antibodies are predominately catabolized by lysosomal enzymes to small peptides and amino acids. No drug interactions have been described to date.,(See Summary)
253,Obeticholic acid,Edoxaban,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Edoxaban is a substrate of carboxylesterase 1, CYP3A4/5 and P-gp. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
254,Obeticholic acid,Efavirenz,No Interaction Expected,NA,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Efavirenz is a substrate and inducer of CYP3A4. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
255,Obeticholic acid,Elbasvir/Grazoprevir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Elbasvir and grazoprevir are substrates of CYP3A4 and P-gp. Grazoprevir is also a substrate of OATP1B and possibly BCRP. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the Zepatier SmPC contraindicates its use in patients with moderate or severe hepatic impairment.,(See Summary)
256,Obeticholic acid,Eletriptan,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as eletriptan is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the eletriptan SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
257,Obeticholic acid,Eliglustat,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eliglustat is metabolized primarily by CYP2D6 and to a lesser extent by CYP3A4, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
258,Obeticholic acid,Eltrombopag,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eltrombopag is metabolized through multiple pathways including CYP1A2, CYP2C8, UGT1A1, and UGT1A3. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
259,Obeticholic acid,Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Elvitegravir and cobicistat are metabolized by CYP3A4; emtricitabine and tenofovir alafenamide are excreted renally. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
260,Obeticholic acid,Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir-DF (EVG/c/FTC/TDF),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Elvitegravir and cobicistat are metabolized by CYP3A4; emtricitabine and tenofovir-DF are excreted renally. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
261,Obeticholic acid,Empagliflozin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Empagliflozin is metabolized by UGTs and is a substrate of P-gp, BCRP, OAT3, and OATP1B1/1B3. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
262,Obeticholic acid,Emtricitabine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Emtricitabine is excreted renally. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
263,Obeticholic acid,Emtricitabine/Tenofovir alafenamide (FTC/TAF),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Emtricitabine and tenofovir alafenamide are excreted renally. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
264,Obeticholic acid,"Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)",No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Emtricitabine and tenofovir-DF are excreted renally. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
265,Obeticholic acid,Enalapril,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enalapril is a prodrug hydrolysed in the liver to enalaprilat. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
266,Obeticholic acid,Enoxaparin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enoxaparin does not undergo cytochrome metabolism but is desulphated and depolymerised in the liver, and is excreted predominantly renally. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
267,Obeticholic acid,Entecavir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Entecavir is mainly excreted unchanged by the kidney by both glomerular filtration and active transport. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
268,Obeticholic acid,Eplerenone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eplerenone is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the eplerenone SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
269,Obeticholic acid,Epoetin alfa,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is no evidence that treatment with epoetin-alfa-2a alters the metabolism of other medicinal products.,(See Summary)
270,Obeticholic acid,Epoprostenol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Epoprostenol is rapidly hydrolysed; there does not appear to be any involvement with CYP isoenzymes or transporter proteins. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
271,Obeticholic acid,Eprosartan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eprosartan is largely excreted in bile and urine as unchanged drug. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the eprosartan SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
272,Obeticholic acid,Ergometrine (ergonovine),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ergometrine (ergonovine) is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the ergometrine SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
273,Obeticholic acid,Ergotamine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ergotamine is metabolized by CYP3A4, which is not affected by obeticholic acid. Note: the ergotamine SmPC contraindicates its use in patients with hepatic impairment.",(See Summary)
274,Obeticholic acid,Erlotinib,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Erlotinib is a substrate for CYP3A4, CYP1A2, and P-gp. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: erlotinib has been associated rarely with hepatic failure, especially in the case of previous liver disease or concomitant hepatotoxic medications (such as obeticholic acid). Periodic liver function testing should be carried out in such patients.",(See Summary)
275,Obeticholic acid,Ertapenem,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ertapenem undergoes minimal metabolism and is mainly excreted unchanged by the kidney by glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
276,Obeticholic acid,Erythromycin,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Erythromycin is a substrate and inhibitor of CYP3A4, P-gp, and OATP. These pathways are not affected by obeticholic acid; however, erythromycin is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: erythromycin has been infrequently reported with hepatic dysfunction including increased liver enzymes and/or cholestatic hepatitis, with or without jaundice. Carry out periodic liver function testing when coadministering with obeticholic acid, which may also cause drug-induced liver injury.",(See Summary)
277,Obeticholic acid,Escitalopram,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Escitalopram is metabolized by CYP2C19, CYP2D6, and CYP3A4, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
278,Obeticholic acid,Eslicarbazepine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eslicarbazepine is partly eliminated unchanged renally and partly glucuronidated by UGT2B4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
279,Obeticholic acid,Esomeprazole,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Esomeprazole is metabolized by CYP2C19 and CYP3A4, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
280,Obeticholic acid,Estazolam,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estazolam is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
281,Obeticholic acid,Estradiol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolized by CYP3A4 and CYP1A2 and is glucuronidated. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
282,Obeticholic acid,Estramustine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estramustine is dephosphorylated and minimal data show it not to undergo any form of CYP metabolism. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
283,Obeticholic acid,Etanercept,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant is unlikely.,(See Summary)
284,Obeticholic acid,Etelcalcetide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data suggest etelcalcetide is not metabolized by CYP450 nor transported by common transporter proteins.,(See Summary)
285,Obeticholic acid,Ethambutol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolized by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and urine (50%). These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
286,Obeticholic acid,Ethinylestradiol,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Multiple P450 isoforms are involved in the metabolism of ethinylestradiol, with CYP3A4 and CYP2C9 as the major contributing enzymes. These pathways are not affected by obeticholic acid; however, ethinylestradiol is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
287,Obeticholic acid,Ethosuximide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethosuximide is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
288,Obeticholic acid,Etonogestrel (implant),No Interaction Expected,NA,"Coadministration with an etonogestrel-containing progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the Nexplanon SmPC contraindicates its use in patients with severe hepatic disease.",(See Summary)
289,Obeticholic acid,Etonogestrel (vaginal ring),No Interaction Expected,NA,"Coadministration with etonogestrel as a combined vaginal ring (CVR) has not been studied. Etonogestrel is metabolized by CYP3A4 and is coformulated in the CVR with ethinylestradiol, which is mainly metabolized by hydroxylation with CYP3A4 and CYP2C9 as the major contributing enzymes. These pathways are not affected by obeticholic acid; however, ethinylestradiol is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. However, due to the local action of ethinylestradiol, this is unlikely to be clinically relevant. Note: the Nuvaring SmPC contraindicates its use in patients with severe hepatic disease.",(See Summary)
290,Obeticholic acid,Etoposide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Etoposide is mainly metabolized by CYP3A4 and UGT1A1, which are not affected by obeticholic acid. However, the risk of hepatotoxicity may be potentially increased as both drugs can cause drug-induced liver damage. Periodic liver function testing should be carried out.",(See Summary)
291,Obeticholic acid,Etoricoxib,Potential Weak Interaction,NA,"Coadministration has not been studied. Etoricoxib is metabolized by multiple CYP enzymes including CYP3A4. In vitro studies suggest etoricoxib is metabolized by CYP1A1. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. However, etoricoxib is a weak BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin. Note: The etoricoxib SmPC contraindicates its use in patients with severe liver impairment.",(See Summary)
292,Obeticholic acid,Etravirine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etravirine is metabolized by CYPs 3A4, 2C9, and 2C19, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
293,Obeticholic acid,Eucalyptus globulus,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eucalyptus is a mild to moderate inhibitor of CYP3A4. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
294,Obeticholic acid,Everolimus,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Everolimus is metabolized by CYP3A4, which is not affected by obeticholic acid; however, everolimus is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
295,Obeticholic acid,Exemestane,Potential Weak Interaction,NA,"Coadministration has not been studied. Exemestane is metabolized by CYP3A4 and aldo-keto reductase, which are not affected by obeticholic acid; however, exemestane is a weak inhibitor of BSEP in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin.",(See Summary)
296,Obeticholic acid,Exenatide,No Interaction Expected,NA,Coadministration with exenatide has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exenatide is eliminated via glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ,(See Summary)
297,Obeticholic acid,Ezetimibe,Potential Weak Interaction,NA,"Coadministration has not been studied. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7. These pathways are not affected by obeticholic; however, ezetimibe is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin. [Note: use of ezetimibe is not recommended in moderate to severe hepatic dysfunction.]",(See Summary)
298,Obeticholic acid,Famotidine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famotidine is eliminated by renal excretion via OAT3 (65-70%) and by metabolic routes (30-35%). Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
299,Obeticholic acid,Febuxostat,Potential Weak Interaction,NA,"Coadministration has not been studied. Febuxostat is extensively metabolized by multiple P450 (CYPs 1A1, CYP1A2, CYP2C8 and CYP2C9) and UGT enzymes (UGTs 1A1, 1A8, and 1A9). Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic does not interact with any of the other pathways involved but febuxostat is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
300,Obeticholic acid,Felodipine,Potential Weak Interaction,NA,"Coadministration has not been studied. Felodipine is metabolized by CYP3A4, which is not affected by obeticholic acid. However, felodipine is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin.",(See Summary)
301,Obeticholic acid,Fenofibrate,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Fenofibrate is metabolized by multiple enzyme pathways (esterases, UGT2B7 and UGT1A1) which are not affected by obeticholic acid. However, fenofibrate is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. [Note, fenofibrate is contraindicated in severe hepatic disease including biliary cirrhosis in the European SmPC, and the US Prescribing Information contraindicates it in active liver disease.]",(See Summary)
302,Obeticholic acid,Fentanyl,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
303,Obeticholic acid,Fexofenadine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine undergoes negligible metabolism and is mainly eliminated unchanged in the faeces. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
304,Obeticholic acid,Filgrastim,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP involvement has not been displayed with filgrastim and it is mainly eliminated by neutrophil-mediated clearance. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
305,Obeticholic acid,Finasteride,Potential Weak Interaction,NA,"Coadministration has not been studied. Finasteride is metabolized by CYP3A4, which is not affected by obeticholic acid; however, finasteride is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
306,Obeticholic acid,Fingolimod,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fingolimod is metabolized mainly by CYP4F2. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the fingolimod SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
307,Obeticholic acid,Fish oils,No Interaction Expected,NA,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely.",(See Summary)
308,Obeticholic acid,Flecainide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flecainide is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
309,Obeticholic acid,Flibanserin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flibanserin is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the flibanserin prescribing information contraindicates its use in patients with hepatic impairment.",(See Summary)
310,Obeticholic acid,Flucloxacillin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucloxacillin is mainly eliminated renally, partly by glomerular filtration and partly by active secretion via OAT1. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
311,Obeticholic acid,Fluconazole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluconazole is mainly eliminated renally by glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
312,Obeticholic acid,Flucytosine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucytosine is metabolized to 5-fluorouracil which undergoes further metabolism by dihydropyrimidine dehydrogenase. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
313,Obeticholic acid,Fludarabine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludarabine phosphate is rapidly hydrolyzed (non-CYP mediated) to 2F-ara-A, the principal metabolite, which is then eliminated renally. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
314,Obeticholic acid,Fludrocortisone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolized in the liver to inactive metabolites, possibly via CYP3A4. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
315,Obeticholic acid,Fluindione,Potential Weak Interaction,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluindione is metabolized by CYP2C9 (major) and CYP1A2 (minor). Obeticholic acid may increase the exposure of CYP1A2 substrates such as fluindione but this is unlikely to be clinically significant.,(See Summary)
316,Obeticholic acid,Flunisolide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide is metabolized primarily by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
317,Obeticholic acid,Fluoxetine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
318,Obeticholic acid,Flupentixol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flupentixol is metabolized by sulfoxidation and dealkylation and is a substrate of UGT. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
319,Obeticholic acid,Fluphenazine,Potential Weak Interaction,NA,"Coadministration has not been studied. Fluphenazine is predominantly metabolized via CYP2D6, which is not affected by obeticholic acid. However, fluphenazine is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin.",(See Summary)
320,Obeticholic acid,Flurazepam,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flurazepam metabolism is likely by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the flurazepam SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
321,Obeticholic acid,Flurbiprofen,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flurbiprofen is metabolized by CYP2C9 and UGT2B7, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
322,Obeticholic acid,Fluticasone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluticasone is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
323,Obeticholic acid,Fluvastatin,Potential Weak Interaction,NA,"Coadministration has not been studied. Fluvastatin is metabolized mainly by CYP2C9, which is not affected by obeticholic acid; however, fluvastatin is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: use of fluvastatin in active liver disease is contraindicated.",(See Summary)
324,Obeticholic acid,Fluvoxamine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvoxamine is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
325,Obeticholic acid,Folic acid,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases.,(See Summary)
326,Obeticholic acid,Fondaparinux,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fondaparinux does not undergo cytochrome metabolism but is eliminated predominantly renally. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
327,Obeticholic acid,Formoterol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation being another pathway. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
328,Obeticholic acid,Fosamprenavir,Potential Interaction,NA,"Coadministration has not been studied. Fosamprenavir is metabolized by CYP3A4, which is not affected by obeticholic acid; however, fosamprenavir is a weak BSEP inhibitor in vitro. Ritonavir, with which fosamprenavir is prescribed, is a strong BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin. ",(See Summary)
329,Obeticholic acid,Foscarnet,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Foscarnet is mainly renally eliminated. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
330,Obeticholic acid,Fosinopril,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fosinopril is a prodrug metabolized in the liver by a non-CYP mechanism to the active metabolite. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
331,Obeticholic acid,Frovatriptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Frovatriptan is metabolized by CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the frovatriptan SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
332,Obeticholic acid,Furosemide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is a substrate of UGTs 1A1, 1A9, and 2B7 and is excreted in the urine. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces. ",(See Summary)
333,Obeticholic acid,Gabapentin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is no evidence of gabapentin metabolism in humans and it is eliminated unchanged solely by renal excretion with little data on transporters used. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
334,Obeticholic acid,Gadopentetate (gadolinium),No Interaction Expected,NA,Coadministration has not been studied but a clinically significant interaction is unlikely. Gadolinium is not metabolized and is excreted unchanged by the kidneys.,(See Summary)
335,Obeticholic acid,Garlic,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Garlic induces intestinal CYP3A4 and/or P-gp. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
336,Obeticholic acid,Gefitinib,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Gefitinib is metabolized by CYP3A4 and CYP2D6, which are not affected by obeticholic acid; however, gefitinib is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
337,Obeticholic acid,Gemcitabine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemcitabine is metabolized in the liver by cytidine deaminase to an inactive metabolite. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces. ",(See Summary)
338,Obeticholic acid,Gemfibrozil,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemfibrozil is metabolized mainly by UGT2B7, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: use of gemfibrozil in hepatic impairment is contraindicated.]",(See Summary)
339,Obeticholic acid,Gentamicin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gentamicin is eliminated unchanged predominantly via renal glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
340,Obeticholic acid,GHB (Gamma-hydroxybutyrate),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of GHB is not well characterised but may involve CYP3A4 which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
341,Obeticholic acid,Ginger (Zingiber officinale),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gingerols moderately inhibit CYP3A4 in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
342,Obeticholic acid,Ginkgo biloba,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with standard doses (up to 240 mg) of Ginkgo biloba.,(See Summary)
343,Obeticholic acid,Ginseng,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely.",(See Summary)
344,Obeticholic acid,Glecaprevir/Pibrentasvir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glecaprevir and pibrentasvir are metabolized by CYP3A4 and are substrates of P-gp and/or BCRP. Glecaprevir is also a substrate of OATP1B1/3. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the Mavyret prescribing information contraindicates its use in patients with severe hepatic impairment.,(See Summary)
345,Obeticholic acid,Glibenclamide (Glyburide),Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Glibenclamide is mainly metabolized by CYP3A4 and to a lesser extent by CYP2C9, which are not affected by obeticholic acid. However, glibenclamide is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: the glibenclamide SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
346,Obeticholic acid,Gliclazide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gliclazide is metabolized by CYP2C9, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the gliclazide SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
347,Obeticholic acid,Glimepiride,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Glimepiride is metabolized by CYP2C9, which is not affected by obeticholic acid. However, glimepiride is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
348,Obeticholic acid,Glipizide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glipizide is mainly metabolized by CYP2C9, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the glipizide SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
349,Obeticholic acid,Glycerol phenylbutyrate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glycerol phenylbutyrate is metabolized by pancreatic lipases, beta-oxidation, and glutamine conjugation, and then eliminated in the urine. Glycerol phenylbutyrate has been shown to be a weak inducer of CYP3A4 but obeticholic acid is not affected by CYP3A4 inducers. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
350,Obeticholic acid,Goldenseal (Hydrastis canadensis),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant concentration is unlikely. Goldenseal is a CYP3A4 inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
351,Obeticholic acid,Goserelin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is minimal metabolism of goserelin and no clinically relevant accumulation with higher doses of the implant. Goserelin is renally cleared with no dose alteration required in renal or hepatic impairment.,(See Summary)
352,Obeticholic acid,Granisetron,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Granisetron is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
353,Obeticholic acid,Grapefruit juice,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance an interaction is unlikely. Grapefruit juice inhibits intestinal CYP3A4. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
354,Obeticholic acid,Grape seed extract,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Grape seed extract appears to mildly inhibit CYP3A4. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
355,Obeticholic acid,Green tea (Camellia sinensis),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Studies have shown variable CYP involvement with green tea metabolism but the overall effect is likely negligible. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
356,Obeticholic acid,Griseofulvin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Griseofulvin is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
357,Obeticholic acid,Halofantrine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halofantrine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
358,Obeticholic acid,Haloperidol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Haloperidol undergoes glucuronidation (UGT2B7>1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4, CYP2D6). Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
359,Obeticholic acid,Heparin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as heparin is cleared by the reticuloendothelial system and is renally excreted. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
360,Obeticholic acid,Heroin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Heroin is rapidly metabolized by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
361,Obeticholic acid,Hydralazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydralazine is metabolized by hydroxylation, conjugation with glucuronic acid and by N-acetylation. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
362,Obeticholic acid,Hydrochlorothiazide,No Interaction Expected,NA,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolized and is cleared by the kidneys. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
363,Obeticholic acid,Hydrocodone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocodone is metabolized by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
364,Obeticholic acid,Hydrocortisone (topical),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Following topical application to most areas of normal skin, only minimal amounts of the drug reach the dermis and subsequently the systemic circulation.",(See Summary)
365,Obeticholic acid,Hydromorphone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: use of hydromorphone in patients with ANY degree of hepatic impairment is contraindicated in the European SmPC, but the US Prescribing Information does not recommend it for patients with severe hepatic impairment and suggests a dose reduction for patients with moderate hepatic impairment.]",(See Summary)
366,Obeticholic acid,Hydroxychloroquine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine is metabolized (in part) by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: the European SmPC for hydroxychloroquine recommends caution in impaired hepatic function.]",(See Summary)
367,Obeticholic acid,Hydroxyzine,Potential Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxyzine is metabolized by alcohol dehydrogenase and CYP3A4/5. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note, as hydroxyzine elimination is impaired in patients with hepatic dysfunction, daily dose or dose frequency should be reduced in patients with impaired liver function.]",(See Summary)
368,Obeticholic acid,Hyoscine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hyoscine acts predominantly locally and undergoes minimal absorption.,(See Summary)
369,Obeticholic acid,Ibalizumab-uiyk,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab: based on ibalizumab’s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",(See Summary)
370,Obeticholic acid,Ibandronic acid,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant is unlikely. The portion of ibandronate that is not removed from the circulation via bone absorption is eliminated unchanged by the kidney (approximately 50% of the absorbed dose). However, administration of ibandronate should be separated from food or other medicinal products. Fasting should be continued for at least 30 minutes after taking ibandronic acid. [Note: this interaction is not specific for obeticholic acid, but for any medication taken with ibandronic acid.] ",(See Summary)
371,Obeticholic acid,Ibuprofen,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
372,Obeticholic acid,Idarubicin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Idarubicin is converted to idarubicinol by aldo-keto reductase. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the idarubicin SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
373,Obeticholic acid,Iloperidone,Potential Weak Interaction,NA,"Coadministration has not been studied. Iloperidone is metabolized by CYP3A4 and CYP2D6, which are not affected by obeticholic acid. However, iloperidone is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
374,Obeticholic acid,Iloprost,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloprost is metabolized by beta-oxidation of the carboxyl side chain with only a minor role for CYP metabolism. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
375,Obeticholic acid,Imatinib,Potential Weak Interaction,NA,"Coadministration has not been studied. Imatinib is primarily metabolized by CYP3A4 and to a lesser extent by CYPs 1A2, 2D6, 2C9, and 2C19. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. In addition, imatinib is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Note: imatinib has been associated with hepatobiliary disorders and concomitant hepatotoxic medications (such as obeticholic acid) may increase the risk of adverse events.",(See Summary)
376,Obeticholic acid,Imipenem,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem is metabolized renally and is predominantly eliminated in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
377,Obeticholic acid,Imipramine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipramine is metabolized by CYP3A4, CYP2C19, and CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant given the multiple pathways involved. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
378,Obeticholic acid,Indacaterol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indacaterol is metabolized by CYP3A4 and transported by P-gp. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
379,Obeticholic acid,Indapamide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is a substrate of CYPs 2C9, 2D6, and 3A4 in vitro. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
380,Obeticholic acid,Indinavir,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Indinavir is metabolized by CYP3A4, which is not affected by obeticholic acid; however, indinavir and coprescribed ritonavir are BSEP inhibitors. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
381,Obeticholic acid,Indometacin,Potential Weak Interaction,NA,"Coadministration has not been studied. Indometacin is predominantly acylated and then glucuronidated. These pathways are not affected by obeticholic acid. However, indometacin is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
382,Obeticholic acid,Insulin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
383,Obeticholic acid,Inula racemosa,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alantolactone, a component of Inula racemosa, moderately inhibits CYP3A4 in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
384,Obeticholic acid,Iodine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iodides are excreted mainly in the urine with smaller amounts excreted in the faeces, sweat and saliva.",(See Summary)
385,Obeticholic acid,Ipilimumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ipilimumab is not metabolized by cytochrome P450 and no drug interactions were involved in studies involving multiple CYP isozymes. However, the risk of hepatotoxicity may be potentially increased as both drugs can cause drug-induced liver injury. Closely monitor liver function. ",(See Summary)
386,Obeticholic acid,Ipratropium bromide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ipratropium bromide is metabolized by esterases. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
387,Obeticholic acid,Irbesartan,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Irbesartan is metabolized by via glucuronidation and oxidation (mainly CYP2C9). These pathways are not affected by obeticholic acid; however, irbesartan is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
388,Obeticholic acid,Irinotecan,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Irinotecan is a substrate of CYP3A4, P-gp, and UGT1B1, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
389,Obeticholic acid,Iron supplements,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
390,Obeticholic acid,Isavuconazole,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isavuconazole is metabolized by CYP3A4/5, which is not affected by obeticholic acid.",(See Summary)
391,Obeticholic acid,Isoflurane,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoflurane is mainly eliminated unchanged by the lungs but a small amount is metabolized by CYP2E1. This pathway is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
392,Obeticholic acid,Isoniazid,Potential Weak Interaction,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoniazid is metabolized by N-acetyl transferase and CYP2E1. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: use of isoniazid should be carefully monitored with patients with current chronic liver disease. Severe and sometimes fatal hepatitis associated with isoniazid therapy may occur and may develop even after many months of treatment.],(See Summary)
393,Obeticholic acid,Isosorbide mononitrate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isosorbide mononitrate is completely absorbed and is not subject to first-pass metabolism by the liver. It is excreted mainly in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
394,Obeticholic acid,Isotretinoin,Potential Weak Interaction,NA,"Coadministration has not been studied. Isotretinoin is metabolized mainly by CYP2C8 and CYP3A4 with participation from CYP2B6 and CYP2C9 and no single isoform appearing to have a predominant role. Obeticholic acid does not interact with these pathways but isotretinoin is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Note: the isotretinoin SmPC contraindicates its use in patients with hepatic insufficiency.",(See Summary)
395,Obeticholic acid,Ispaghula husk,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The mode of action of ispaghula husk is physical and does not depend on absorption into the systemic circulation.,(See Summary)
396,Obeticholic acid,Isradipine,Potential Weak Interaction,NA,"Coadministration has not been studied. Isradipine is metabolized by CYP3A4, which is not affected by obeticholic acid; however, isradipine is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
397,Obeticholic acid,Itraconazole,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Itraconazole is metabolized by CYP3A4, which is not affected by obeticholic acid. However, itraconazole is an inhibitor of BSEP. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. ",(See Summary)
398,Obeticholic acid,Ivabradine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ivabradine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the ivabradine SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
399,Obeticholic acid,Ivermectin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ivermectin is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
400,Obeticholic acid,Ixazomib,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ixazomib is metabolized by multiple CYP and non-CYP enzymes. Coadministration with strong CYP3A4 and CYP1A2 inhibitors did not result in clinically meaningful change in the exposure of ixazomib. Note: ixazomib has been associated uncommonly with drug-induced liver injury, hepatocellular injury, hepatic steatosis, hepatitis cholestatic, and hepatotoxicity. Carry out periodic liver function testing when coadministering with obeticholic acid, which may also cause drug-induced liver injury.",(See Summary)
401,Obeticholic acid,Kava kava (Piper methysticum),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Kava kava inhibits CYP3A4 in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
402,Obeticholic acid,Ketamine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ketamine is mainly metabolized by CYP3A4 and to a lesser extent by CYP2B6 and CYP2C9 in the range of concentrations used in anaesthesia. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
403,Obeticholic acid,Ketoconazole,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Ketoconazole is metabolized by CYP3A4 but also inhibits CYP3A4 and P-gp. Obeticholic acid does not interact with these pathways; however, ketoconazole is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
404,Obeticholic acid,Ketoprofen,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ketoprofen is metabolized by UGTs, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
405,Obeticholic acid,Labetalol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated by UGTs 1A1 and 2B7, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: labetalol has been associated with hepatocellular injury. The SmPC for labetalol advises extra caution and dose reduction in patients with hepatic impairment.",(See Summary)
406,Obeticholic acid,Lacidipine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacidipine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note, caution is advised in patients with hepatic impairment.]",(See Summary)
407,Obeticholic acid,Lacosamide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacosamide is metabolized by CYPs 2C9, 2C19, and 3A4, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
408,Obeticholic acid,Lactulose,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lactulose to lactic acid occurs via gastrointestinal microbial flora only.,(See Summary)
409,Obeticholic acid,Lamivudine (HBV),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamivudine is predominately cleared unchanged by renal excretion. The likelihood of metabolic interactions with lamivudine and other medicinal products is low due to the small extent of lamivudine hepatic metabolism (5-10%) and low plasma protein binding. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
410,Obeticholic acid,Lamivudine (HIV),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamivudine is excreted renally. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
411,Obeticholic acid,Lamotrigine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamotrigine is metabolized by UGT1A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
412,Obeticholic acid,Lanreotide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The limited data available indicate the somatostatin analogues, such as lanreotide, may increase concentrations of CYP450 substrates but this is unlikely to have a clinically significant effect on obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
413,Obeticholic acid,Lansoprazole,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lansoprazole is mainly metabolized via CYP2C19, with CYP3A4 also contributing to the metabolism. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
414,Obeticholic acid,Lapatinib,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Lapatinib is metabolized by CYP3A4, which is not affected by obeticholic acid; however, lapatinib is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
415,Obeticholic acid,Ledipasvir/Sofosbuvir,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ledipasvir and sofosbuvir are substrates of P-gp and BCRP, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
416,Obeticholic acid,Lenalidomide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lenalidomide undergoes limited metabolism and is not metabolized by cytochrome P450 enzymes. It does not induce CYPs or inhibit CYPs, UGT1A1, P-gp, and OATP1B1. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
417,Obeticholic acid,Lercanidipine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is mainly metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the lercanidipine SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
418,Obeticholic acid,Letrozole,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Letrozole is metabolized by CYP3A4 and CYP2A6 to carbinol, an inactive metabolite. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
419,Obeticholic acid,Levetiracetam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levetiracetam is not extensively metabolized in humans and production of the primary metabolite is not mediated by liver cytochrome P450 isoenzymes. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
420,Obeticholic acid,Levocetirizine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as less than 14% of a dose of levocetirizine is metabolized. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
421,Obeticholic acid,Levofloxacin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as levofloxacin is mainly excreted in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces. ",(See Summary)
422,Obeticholic acid,Levomepromazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levomepromazine is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
423,Obeticholic acid,Levonorgestrel (COC),Potential Interaction,NA,"Coadministration of a levonorgestrel-containing combined oral contraceptive (COC) has not been studied and is not recommended. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Ethinylestradiol is mainly metabolized by hydroxylation with CYP3A4 and CYP2C9 as the major contributing enzymes. These pathways are not affected by obeticholic acid; however, ethinylestradiol is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: the Levest SmPC contraindicates its use in patients with severe hepatic disease.",(See Summary)
424,Obeticholic acid,Levonorgestrel (Emergency Contraception),No Interaction Expected,NA,Coadministration with levonorgestrel for emergency contraception has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
425,Obeticholic acid,Levonorgestrel (HRT),No Interaction Expected,NA,Coadministration with levonorgestrel as hormone replacement therapy (HRT) has not been studied but a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
426,Obeticholic acid,Levonorgestrel (implant),No Interaction Expected,NA,Coadministration with a levonorgestrel progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the Implanon Prescribing Information contraindicates its use in patients with active liver disease.,(See Summary)
427,Obeticholic acid,Levonorgestrel (IUD),No Interaction Expected,NA,Coadministration with a levonorgestrel intrauterine device (IUD) has not been studied but there is little potential for an interaction given the local mechanism of action of levonorgestrel. Note: the Mirena SmPC contraindicates its use in patients with severe or acute liver disease.,(See Summary)
428,Obeticholic acid,Levonorgestrel (POP),No Interaction Expected,NA,Coadministration with a levonorgestrel progestogen-only pill (POP) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the Implanon Prescribing Information contraindicates its use in patients with severe hepatic disease.,(See Summary)
429,Obeticholic acid,Levothyroxine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levothyroxine is metabolized by deiodination (by enzymes of deiodinase family) and glucuronidation. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
430,Obeticholic acid,Lidocaine (Lignocaine),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lidocaine is metabolized by CYP1A2 and CYP3A4. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid has no effect on CYP3A4. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
431,Obeticholic acid,Linaclotide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linaclotide is metabolized locally within the gastrointestinal tract and extensive studies have shown no CYP or transporter interactions occur.,(See Summary)
432,Obeticholic acid,Linagliptin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Linagliptin is mainly eliminated as parent compound in faeces. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
433,Obeticholic acid,Linezolid,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant is unlikely. Linezolid is not metabolized by CYP450 and is not known to affect any of the key metabolic enzymes. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
434,Obeticholic acid,Liraglutide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is not expected. Liraglutide is degraded by endogenous endopeptidases with no specific organ having been identified as a major route of elimination. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
435,Obeticholic acid,Lisinopril,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril does not undergo metabolism and is excreted entirely unchanged into the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: lisinopril exposure is increased in cirrhotic patients due to decreased clearance.],(See Summary)
436,Obeticholic acid,Lithium ,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lithium is mainly eliminated unchanged through the kidneys and is freely filtered at a rate that is dependent upon the glomerular filtration rate, therefore, no pharmacokinetic interaction is expected. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
437,Obeticholic acid,Lixisenatide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lixisenatide is a peptide and is not metabolized by cytochrome P450. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
438,Obeticholic acid,Lofexidine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lofexidine is mainly metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
439,Obeticholic acid,Loperamide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is mainly metabolized by CYP3A4 and CYP2C8 and is a substrate of P-gp, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note, use with caution in patients with hepatic impairment as no pharmacokinetic data are available and in such patients reduced first pass metabolism may result in a relative overdose leading to CNS toxicity.]",(See Summary)
440,Obeticholic acid,Lopinavir,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Lopinavir is metabolized by CYP3A4, which is not affected by obeticholic acid; however, lopinavir and coprescribed ritonavir are BSEP inhibitors. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Note: the lopinavir/ritonavir SmPC contraindicates its use in patients with severe hepatic impairment. ",(See Summary)
441,Obeticholic acid,Loratadine,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Loratadine is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6. Obeticholic acid has no effect on CYP3A4 or CYP2D6. However, loratadine is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
442,Obeticholic acid,Lorazepam,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lorazepam is metabolized by multiple UGTs, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the lorazepam SmPC contraindicates its use in patients with severe hepatic impairment. ",(See Summary)
443,Obeticholic acid,Lormetazepam,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lormetazepam is metabolized by multiple UGTs, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the lormetazepam SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
444,Obeticholic acid,Losartan,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Losartan is metabolized to an active carboxylated acid metabolite by CYP2C9, which is not affected by obeticholic acid; however, losartan is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: the losartan SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
445,Obeticholic acid,Lovastatin,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Lovastatin is metabolized by CYP3A4 and OATP1B1, which are not affected by obeticholic acid; however, lovastatin is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
446,Obeticholic acid,LSD (Lysergic acid diethylamide),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. LSD (lysergic acid diethylamide) is metabolized to O-H-LSD and N-desmethyl-LSD partly by CYP (unknown isoenzyme). Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
447,Obeticholic acid,Lubiprostone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lubiprostone rapidly occurs within the stomach and jejunum, most likely in the absence of any systemic absorption. In vitro studies show that no CYP mediated interactions occur.",(See Summary)
448,Obeticholic acid,Lumacaftor/Ivacaftor,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lumacaftor is minimally metabolized (via oxidation and glucuronidation), while the majority of lumacaftor is excreted unchanged in the faeces. Ivacaftor is extensively metabolized, primarily by CYP3A, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
449,Obeticholic acid,Lumefantrine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lumefantrine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
450,Obeticholic acid,Lymecycline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lymecycline is not metabolized and is excreted unchanged by renal and biliary routes. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
451,Obeticholic acid,Macitentan,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Macitentan is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the macitentan SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
452,Obeticholic acid,Macrogol,No Interaction Expected,NA,"Coadministration has not been studied but a clinically significant interaction with is unlikely. Macrogol is unabsorbed from the gastrointestinal tract and is excreted, unaltered, in faeces. Any macrogol that does enter the circulation is excreted in the urine.",(See Summary)
453,Obeticholic acid,Magnesium,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Magnesium is eliminated in the kidney, mainly by glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
454,Obeticholic acid,Maprotiline,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Maprotiline is metabolized predominantly by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
455,Obeticholic acid,Maraviroc,No Interaction Expected,NA,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Maraviroc is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
456,Obeticholic acid,Mebeverine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mebeverine is metabolized by hydrolysis. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
457,Obeticholic acid,Medroxyprogesterone (depot injection),Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Medroxyprogesterone is metabolized by CYP3A4, which is not affected by obeticholic acid; however, medroxyprogesterone is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: the Depo-Provera SmPC contraindicates its use in patients with severe hepatic disease.",(See Summary)
458,Obeticholic acid,Medroxyprogesterone (oral),Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Medroxyprogesterone is metabolized by CYP3A4, which is not affected by obeticholic acid; however, medroxyprogesterone is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: the Provera SmPC contraindicates its use in patients with acute liver disease.",(See Summary)
459,Obeticholic acid,Mefenamic acid,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolized by CYP2C9 and glucuronidated by UGTs 2B7 and 1A9. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
460,Obeticholic acid,Mefloquine,No Interaction Expected,NA,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Mefloquine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: the use of mefloquine in patients with severe impairment of liver function is contraindicated in the European SmPC for mefloquine, but not in the US Prescribing Information.]",(See Summary)
461,Obeticholic acid,Melatonin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Melatonin is metabolized by CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
462,Obeticholic acid,Meloxicam,Potential Weak Interaction,NA,"Coadministration has not been studied. Meloxicam is a substrate of CYP2C9 (major) and CYP3A4 (minor), which are not affected by obeticholic acid. However, meloxicam is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin.",(See Summary)
463,Obeticholic acid,Memantine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Memantine does not appear to undergo CYP metabolism and is renally excreted. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
464,Obeticholic acid,Mephedrone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mephedrone is metabolized mainly by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
465,Obeticholic acid,Mercaptopurine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Mercaptopurine is converted into active thioguanine nucleotides by the enzyme xanthine oxidase and undergoes methylation by thiopurine methyltransferase to form S- methylated nucleotides, which are also cytotoxic. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: ixazomib has been associated commonly with biliary stasis, and hepatotoxicity; and rarely with hepatic necrosis. Coadminister obeticholic acid with caution, as it may also cause drug-induced liver injury.",(See Summary)
466,Obeticholic acid,Meropenem,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is mainly excreted in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
467,Obeticholic acid,Mesalazine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as mesalazine largely acts locally in the gut and is acetylated there.,(See Summary)
468,Obeticholic acid,Metamizole (Dipyrone),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metamizole is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
469,Obeticholic acid,Metformin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is mainly excreted renally and is transported by OCT2. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: metformin is contraindicated with hepatic insufficiency, acute alcohol intoxication, and alcoholism.]",(See Summary)
470,Obeticholic acid,Methadone,Potential Interaction,NA,"Coadministration has not been studied. Methadone is metabolized in the liver mainly via the cytochrome P450 isoenzyme CYP3A4; the isoenzymes CYP2B6, CYP2D6, CYP2C9, CYP2C19, and CYP1A2 are also thought to be involved. Obeticholic acid may increase the exposure of CYP1A2 substrates but the clinical significance of this is unknown. Patients should be monitored for signs and symptoms of methadone toxicity. For patients on a high dose of methadone, the risk for QTc prolongation should be considered. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ",(See Summary)
471,Obeticholic acid,Methamphetamine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methamphetamine is mainly metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
472,Obeticholic acid,Methenamine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methenamine is mainly excreted unchanged in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the methenamine SmPC contraindicates its use in patients with severe liver impairment.,(See Summary)
473,Obeticholic acid,Methotrexate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methotrexate is predominantly eliminated via the kidneys, including active tubular secretion. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the methotrexate SmPC contraindicates its use in patients with severe hepatic impairment (bilirubin levels >5 mg/dL).",(See Summary)
474,Obeticholic acid,Methylcellulose,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
475,Obeticholic acid,Methyldopa,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and elimination a clinically significant interaction is unlikely. Methyldopa is excreted predominantly unchanged via renal glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: methyldopa is contraindicated in active hepatitis and active cirrhosis in its European SmPC and US Prescribing Information.],(See Summary)
476,Obeticholic acid,Methylergonovine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylergonovine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
477,Obeticholic acid,Methylphenidate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylphenidate is metabolized by de-esterification, is not metabolized by cytochrome P450s to a clinically relevant extent, and does not inhibit cytochrome P450s. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ",(See Summary)
478,Obeticholic acid,Methylprednisolone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylprednisolone is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
479,Obeticholic acid,Metoclopramide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note a reduced dosage is recommended in patients with hepatic insufficiency.]",(See Summary)
480,Obeticholic acid,Metolazone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metolazone is largely excreted unchanged in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
481,Obeticholic acid,Metoprolol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is largely metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: in patients with severe hepatic dysfunction a reduction in dosage may be necessary.]",(See Summary)
482,Obeticholic acid,Metronidazole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
483,Obeticholic acid,Mexiletine,Potential Interaction,NA,Coadministration has not been studied. Mexiletine is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates. Consider clinical and ECG monitoring and adapt the dose of mexiletine if required. Obeticholic acid has no effect on CYP2D6. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
484,Obeticholic acid,Mianserin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance an interaction is unlikely. Mianserin is metabolized by CYPs 2D6 and 1A2 and to a lesser extent by CYP3A4. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
485,Obeticholic acid,Miconazole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
486,Obeticholic acid,Midazolam (oral),Potential Weak Interaction,NA,"Coadministration of oral midazolam and obeticholic acid increased both midazolam AUC and Cmax by 2%. No clinically significant interaction occurred. Midazolam is metabolized by CYP3A4, which is not affected by obeticholic acid. However, midazolam is a weak inhibitor of BSEP in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Note: the midazolam SmPC contraindicates its use in patients with severe hepatic impairment.","No clinically relevant interactions were seen when the following drugs were administered as single doses concomitantly with Ocaliva 10 mg once daily: Midazolam 2 mg (CYP3A4 substrate): 2% increase in AUC and Cmax of midazolam.Ocaliva Prescribing Information, Intercept Pharmaceuticals Inc., January 2018.Coadministration of midazolam (2 mg, single dose) and obeticholic acid (10 and 25 mg, once daily) was studied in 48 healthy volunteers in a crossover trial. Midazolam AUC and Cmax both increased by 2% with the 10 mg dose and by 26% and 17% with the 25 mg dose of obeticholic acid.Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Edwards JE, Eliot L, Parkinson A, et al. Adv Ther. 2017, 34(9): 2120–2138."
487,Obeticholic acid,Midazolam (parenteral),Potential Weak Interaction,NA,"Coadministration of parental midazolam has not been studied. Coadministration of oral midazolam and obeticholic acid increased both midazolam AUC and Cmax by 2%. No clinically significant interaction occurred. Midazolam is metabolized by CYP3A4, which is not affected by obeticholic acid. However, midazolam is a weak inhibitor of BSEP in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Note: the midazolam SmPC contraindicates its use in patients with severe hepatic impairment.","No clinically relevant interactions were seen when the following drugs were administered as single doses concomitantly with Ocaliva 10 mg once daily: Midazolam 2 mg (CYP3A4 substrate): 2% increase in AUC and Cmax of midazolam.Ocaliva Prescribing Information, Intercept Pharmaceuticals Inc., January 2018.Coadministration of midazolam (2 mg, single dose) and obeticholic acid (10 and 25 mg, once daily) was studied in 48 healthy volunteers in a crossover trial. Midazolam AUC and Cmax both increased by 2% with the 10 mg dose and by 26% and 17% with the 25 mg dose of obeticholic acid.Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Edwards JE, Eliot L, Parkinson A, et al. Adv Ther. 2017, 34(9): 2120–2138."
488,Obeticholic acid,Mifepristone,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Renal excretion of mifepristone is thought to account for approximately 10% of an oral dose. Mifepristone is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
489,Obeticholic acid,Milk thistle (Silymarin),Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Drug-drug interaction studies suggest that milk thistle has a limited clinical impact on substrates of CYP3A, P-gp, UGT, and OATP; however milk thistle is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. ",(See Summary)
490,Obeticholic acid,Milnacipran,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Milnacipran is mainly eliminated unchanged (50%), and as glucuronides (30%) and oxidative metabolites (20%). Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: no dosage adjustment is necessary for patients with hepatic impairment, but caution should be exercised in patients with severe hepatic impairment. Milnacipran should ordinarily not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease.]",(See Summary)
491,Obeticholic acid,Minoxidil,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Minoxidil is mainly metabolized by UGTs, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
492,Obeticholic acid,Mirabegron,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirabegron is metabolized by multiple pathways including hydrolysis, glucuronidation, and oxidation by CYP2D6 and CYP3A4. It is also a substrate of P-gp. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
493,Obeticholic acid,Mirtazapine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolized to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4. Obeticholic acid may increase the exposure of CYP1A2 substrates. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
494,Obeticholic acid,Misoprostol,Potential Weak Interaction,NA,"Coadministration has not been studied. Misoprostol is predominantly metabolized via fatty acid oxidising systems. Obeticholic acid does not interact with these pathways but misoprostol is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
495,Obeticholic acid,Mitoxantrone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly by CYP450. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
496,Obeticholic acid,Moclobemide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moclobemide is metabolized by multiple pathways, including CYP2C19 and CYP2D6, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
497,Obeticholic acid,Modafinil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Modafinil is largely metabolized by hydrolysis (esterase-mediated) and to a lesser extent by CYP3A4 mediated oxidative metabolism. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
498,Obeticholic acid,Mometasone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
499,Obeticholic acid,Montelukast,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolized by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: montelukast has been associated rarely with hepatitis, including cholestatic, hepatocellular and mixed-pattern liver injury) ",(See Summary)
500,Obeticholic acid,Morphine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Morphine is metabolized by UGT2B7, UGT1A3 with a minor contribution from CYP2D6 and CYP3A4. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the morphine SmPC contraindicates its use in patients with severe liver impairment.",(See Summary)
501,Obeticholic acid,Moxifloxacin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moxifloxacin predominantly undergoes glucuronidation by UGT1A1. Obeticholic acid does not interfere with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
502,Obeticholic acid,Moxonidine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moxonidine is only minimally metabolized and undergoes renal excretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
503,Obeticholic acid,Mycophenolate,Potential Weak Interaction,NA,"Coadministration has not been studied. Mycophenolate undergoes presystemic metabolism to active mycophenolic acid, which then undergoes enterohepatic recirculation and is glucuronidated by UGT1A9 and UGT2B7 to the inactive mycophenolic acid glucuronide. Obeticholic acid does not interact with these pathways but mycophenolate is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin.",(See Summary)
504,Obeticholic acid,Naftidrofuryl,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naftidrofuryl is metabolized to 3 major metabolites primarily by plasma pseudo-choline esterases. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
505,Obeticholic acid,Nalmefene,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies have shown that nalmefene is metabolized by UGTs 2B7, 1A3, and 1A8. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the nalmefene SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
506,Obeticholic acid,Naloxegol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naloxegol is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
507,Obeticholic acid,Naloxone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naloxone is mainly metabolized by UGTs, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
508,Obeticholic acid,Naltrexone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies have shown that neither naltrexone nor its main metabolite (6-beta-naltrexol) is metabolized by CYP450 enzymes. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the naltrexone SmPC contraindicates its use in patients with acute hepatitis or liver failure.,(See Summary)
509,Obeticholic acid,Naproxen,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is a substrate of CYP1A2, CYP2C9, CYP2C8, and multiple UGTs. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid has no effect on CYP2C9, CYP2C8, or UGTs. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
510,Obeticholic acid,Naratriptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naratriptan is metabolized by a wide range of CYP enzymes and is mainly excreted in the urine. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the naratriptan SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
511,Obeticholic acid,Nateglinide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is predominantly metabolized by CYP2C9 and only metabolized by CYP3A4 to a small extent. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the nateglinide SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
512,Obeticholic acid,Nebivolol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nebivolol is metabolized by CYP2D6 followed by glucuronidation. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: the European SmPC contraindicates the use of nebivolol in patients with hepatic insufficiency and the US Prescribing Information recommends an initial dose of 2.5 mg once daily in patients with moderate hepatic impairment.],(See Summary)
513,Obeticholic acid,Nefazodone,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Nefazodone is metabolized mainly by CYP3A4 and inhibits BSEP. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
514,Obeticholic acid,Neostigmine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Neostigmine metabolism has not been well described but limited data suggest metabolism occurs via hydrolysis by cholinesterase with up to 50% of a dose being excreted unchanged in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
515,Obeticholic acid,Nevirapine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Nevirapine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. However, severe and life-threatening hepatoxicity has occurred in patients treated with nevirapine. Coadminister with caution, as obeticholic acid has also been associated with drug-induced liver injury. Closely monitor liver function. Note: the nevirapine SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
516,Obeticholic acid,Nicardipine,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Nicardipine is metabolized by CYP3A4 and to a lesser extent by CYP2D6 and CYP2C8, which are not affected by obeticholic acid. However, nicardipine is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
517,Obeticholic acid,Nicorandil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicorandil metabolism is mainly by denitration of the molecule into the nicotinamide pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
518,Obeticholic acid,Nifedipine,Potential Weak Interaction,NA,"Coadministration has not been studied. Nifedipine is metabolized mainly by CYP3A4, which is not affected by obeticholic acid. However, nifedipine is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin. Note: the nifedipine SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
519,Obeticholic acid,Nilotinib,No Interaction Expected,NA,"Coadministration has not been studied based on metabolism and clearance a clinically significant interaction is unlikely. Nilotinib is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
520,Obeticholic acid,Niraparib,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant is unlikely. Niraparib undergoes minimal oxidative metabolism and, due to high permeability and bioavailability, does not have clinically relevant interactions with P-gp and BCRP transporters. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
521,Obeticholic acid,Nisoldipine,Potential Weak Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nisoldipine is metabolized by CYP3A4, which is not affected by obeticholic acid. However, nisoldipine is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
522,Obeticholic acid,Nitrendipine,Potential Weak Interaction,NA,"Coadministration has not been studied. Nitrendipine is metabolized mainly by CYP3A4, which is not affected by obeticholic acid. However, both drugs are transported by BSEP and nitrendipine is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
523,Obeticholic acid,Nitrofurantoin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 30 to 40% of a nitrofurantoin dose is excreted rapidly in the urine as unchanged nitrofurantoin and some tubular reabsorption may occur in acid urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
524,Obeticholic acid,Nitrous oxide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Most inhaled nitrous oxide is rapidly eliminated unchanged through the lungs. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
525,Obeticholic acid,Nivolumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant is unlikely. Like other protein therapeutics, nivolumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes. ",(See Summary)
526,Obeticholic acid,Norfloxacin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norfloxacin is metabolized by CYP1A2 and is mainly excreted in urine by glomerular filtration and active transport. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
527,Obeticholic acid,Nortriptyline,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nortriptyline is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
528,Obeticholic acid,Nusinersan,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nusinersan is metabolized slowly and predominantly via exonuclease (3'- and 5'-) mediated hydrolysis and is not a substrate, inhibitor, or inducer of CYP450 enzymes. The likelihood of interaction with transporters is low. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
529,Obeticholic acid,Nystatin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Systemic absorption of nystatin from oral or topical dosing is minimal and nystatin is mainly excreted in the faeces. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
530,Obeticholic acid,Obinutuzumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, obinutuzumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes. ",(See Summary)
531,Obeticholic acid,Ocrelizumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ocrelizumab is cleared principally by catabolism into peptides and amino acids and is not expected to interact with drugs metabolized via CYP450 or transported by common transporters.,(See Summary)
532,Obeticholic acid,Ofatumumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, ofatumumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes. ",(See Summary)
533,Obeticholic acid,Ofloxacin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ofloxacin is eliminated unchanged renally by glomerular filtration and active tubular secretion via both cationic and anionic transport systems. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
534,Obeticholic acid,Olanzapine,Potential Interaction,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolized by CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates. The olanzapine SmPC recommends decreasing the olanzapine dose when coadministering a CYP1A2 inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
535,Obeticholic acid,Olaratumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, olaratumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes.",(See Summary)
536,Obeticholic acid,Olmesartan,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Olmesartan medoxomil is de-esterified to the active metabolite olmesartan, which is eliminated in the faeces and urine. Obeticholic acid does not interact with this pathway; however, olmesartan is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. [Note: the European SmPC for olmesartan recommends an initial 10 mg dose of olmesartan (with a maximum of 20 mg daily dose) in moderate hepatic impairment. It does not recommend olmesartan in severe hepatic impairment. No dosage restrictions are given in the US Prescribing Information.]",(See Summary)
537,Obeticholic acid,Omalizumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cytochrome P450 enzymes, efflux pumps and protein-binding mechanisms are not involved in the metabolism and clearance of omalizumab.",(See Summary)
538,Obeticholic acid,Ombitasvir/Paritaprevir/r,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Multiple CYP enzymes and drug transporters, including P-gp, BCRP, and OATP1B are involved in the metabolism of ombitasvir/paritaprevir/ritonavir. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the Viekirax SmPC contraindicates its use in patients with moderate or severe hepatic impairment.",(See Summary)
539,Obeticholic acid,Ombitasvir/Paritaprevir/r + Dasabuvir,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Multiple CYP enzymes and drug transporters, including P-gp, BCRP, and OATP1B are involved in the metabolism ombitasvir/paritaprevir/ritonavir + dasabuvir. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the Viekirax SmPC contraindicates its use in patients with moderate or severe hepatic impairment.",(See Summary)
540,Obeticholic acid,Omeprazole,No Interaction Expected,NA,"Coadministration of 20 mg omeprazole with 10 mg of obeticholic acid increased omeprazole AUC and Cmax by 32% and 33%, respectively. The clinical significance of this interaction is unknown. Omeprazole is mainly metabolized by CYP2C19 and CYP3A4, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.","Proton Pump Inhibitors (omeprazole): Concomitant administration of 20 mg omeprazole once daily with Ocaliva 10 mg once daily resulted in a less than 1.2-fold increase in obeticholic acid exposure. Concomitant administration of 20 mg omeprazole as a single dose with Ocaliva 10 mg once daily resulted in a 32% increase in AUC and a 33% increase in Cmax of omeprazole. The clinical significance is unknown.Ocaliva Prescribing Information, Intercept Pharmaceuticals Inc., January 2018.Coadministration of omeprazole (20 mg single dose and 20 mg, once daily) and obeticholic acid (10 or 20 mg, once daily) was studied in 48 healthy volunteers, in a crossover trial. Omeprazole AUC and Cmax increased by 32% and 33%, respectively with the 10 mg dose and by 36% and 15%, respectively, with the 25 mg dose of obeticholic acid.Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Edwards JE, Eliot L, Parkinson A, et al. Adv Ther. 2017, 34(9): 2120–2138."
541,Obeticholic acid,Ondansetron,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ondansetron is metabolized by multiple CYP enzymes including CYP3A4, CYP2D6, and CYP12A. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: in subjects with moderate or severe hepatic impairment ondansetron clearance is significantly reduced and half-life significantly increased; in such patients, the ondansetron total daily dose should not exceed 8 mg and parenteral or oral administration is recommended.]",(See Summary)
542,Obeticholic acid,Orlistat,Potential Weak Interaction,NA,"Coadministration has not been studied. Orlistat is minimally absorbed after oral doses with about 97% of a dose excreted in the faeces, 83% of which as unchanged orlistat. A clinically significant is unlikely, however, because of its effect on fat absorption in the GI tract, it cannot be ruled out that absorption of obeticholic acid could be reduced. [Note: this interaction is not specific for obeticholic acid, but for any medication taken with orlistat.]",(See Summary)
543,Obeticholic acid,Orphenadrine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Orphenadrine is an inhibitor of CYP2B6, but this enzyme is not involved in the metabolism of obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
544,Obeticholic acid,Oseltamivir,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oseltamivir is converted to oseltamivir carboxylate by esterases, which is then excreted in the urine by glomerular filtration and tubular secretion by OAT1. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
545,Obeticholic acid,Oxaliplatin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxaliplatin undergoes non-enzymatic biotransformation and is eliminated renally by OCT2, MATE2-K and, to a lesser extent, MATE-1. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
546,Obeticholic acid,Oxamniquine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Limited data suggest that oxamniquine is likely to be a substrate of CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
547,Obeticholic acid,Oxazepam,No Interaction Expected,NA,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly metabolized by UGTs, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the oxazepam SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
548,Obeticholic acid,Oxcarbazepine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxcarbazepine is rapidly reduced by cytosolic arylketone reductases to its active metabolite, 10-hydroxycarbazepine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
549,Obeticholic acid,Oxprenolol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxprenolol is largely metabolized by UGTs, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
550,Obeticholic acid,Oxycodone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxycodone is metabolized principally to noroxycodone by CYP3A4 and to oxymorphone by CYP2D6. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: use of oxycodone in patients with moderate to severe hepatic failure is contraindicated in the European SmPC but not in the US Prescribing Information.],(See Summary)
551,Obeticholic acid,Paclitaxel,Potential Weak Interaction,NA,"Coadministration has not been studied. Paclitaxel is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4, which are not affected by obeticholic acid; however, paclitaxel is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
552,Obeticholic acid,Paliperidone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily eliminated renally (possibly via OCT) with minimal metabolism occurring via CYP2D6 and CYP3A4. These pathways are not affected by obeticholic acid. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
553,Obeticholic acid,Pamidronate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pamidronate is not hepatically metabolized and is almost exclusively renally excreted. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
554,Obeticholic acid,Panitumumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, panitumumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes.",(See Summary)
555,Obeticholic acid,Pantoprazole,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pantoprazole is mainly metabolized by CYP2C19, with CYP3A4 also contributing to the metabolism. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
556,Obeticholic acid,Paracetamol (Acetaminophen),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolized by glucuronidation (UGT1A9 (major), UGT1A6, UGT1A1, UGT2B15), sulfation and, to a lesser extent, by oxidation. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
557,Obeticholic acid,Paroxetine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is metabolized mainly by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
558,Obeticholic acid,Peginterferon alfa-2a,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Peginterferon alfa-2a is cleared by both the liver and the kidneys. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
559,Obeticholic acid,Peginterferon alfa-2b,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Peginterferon alfa-2b releases free interferon-alfa-2b soon after administration, which is then renally excreted. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
560,Obeticholic acid,Pembrolizumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Pembrolizumab is primarily metabolised through catabolic pathways and drug-drug interactions are not expected.,(See Summary)
561,Obeticholic acid,Penicillamine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Up to 80% of a penicillamine dose is excreted via the kidneys, predominantly as metabolites and rarely as unchanged drug. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
562,Obeticholic acid,Penicillin V,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
563,Obeticholic acid,Pentamidine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pentamidine is metabolized by CYP1A2 and CYP2D6. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
564,Obeticholic acid,Pentoxifylline,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pentoxifylline has not been well described but some studies indicate oxidation by CYP1A2, reduction by carbonyl reductase, and oxidation by carboxylase. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
565,Obeticholic acid,Perampanel,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perampanel is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
566,Obeticholic acid,Perazine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is demethylated by CYP3A4 and to a lesser extent by CYP2C9 and oxidated by FMO3. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
567,Obeticholic acid,Periciazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of periciazine has not been well characterized but is likely to involve CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
568,Obeticholic acid,Perindopril,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perindopril is hydrolysed to the active metabolite perindoprilat and is metabolized to other inactive metabolites. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
569,Obeticholic acid,Perphenazine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perphenazine is metabolized by CYP2D6. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
570,Obeticholic acid,Pethidine (Meperidine),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolized mainly by CYP2B6 and to a lesser extent by CYP3A4, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the pethidine SmPC contraindicates its use in patients with severe liver impairment.",(See Summary)
571,Obeticholic acid,Phencyclidine (PCP),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phencyclidine is extensively metabolized to inactive metabolites by a variety of metabolic routes (mainly CYP3A4). Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
572,Obeticholic acid,Phenobarbital,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenobarbital undergoes CYP-mediated metabolism and is an inducer of P-gp, CYP450, and UGT. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the phenobarbital SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
573,Obeticholic acid,Phenprocoumon,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenprocoumon is metabolized by CYP2C9 and CYP3A4, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
574,Obeticholic acid,Phenylephrine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenylephrine is metabolized by MAO. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the phenylephrine SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
575,Obeticholic acid,Phenytoin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenytoin is metabolized by CYPs 2C9 and 2C19, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
576,Obeticholic acid,Pilocarpine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with either oral or ocular use. When taken orally, pilocarpine is primarily metabolized by CYP2A6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
577,Obeticholic acid,Pimozide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pimozide is primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6, with some minor contribution from CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
578,Obeticholic acid,Pindolol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is partly metabolized to hydroxymetabolites (possibly by CYP2D6) and partly eliminated unchanged in the urine. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
579,Obeticholic acid,Pioglitazone,Potential Weak Interaction,NA,"Coadministration has not been studied and is not recommended. Pioglitazone is metabolized by mainly CYP2C8 and to a lesser extent by CYPs 3A4, 1A2, and 2C9. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. However, pioglitazone is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. [Note: pioglitazone is contraindicated in hepatic impairment in the European SmPC, but caution is advised in the US Prescribing Information.]",(See Summary)
580,Obeticholic acid,Piperacillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piperacillin is only minimally metabolized and is excreted largely unchanged in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
581,Obeticholic acid,Pipotiazine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
582,Obeticholic acid,Piracetam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piracetam is excreted largely unchanged in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
583,Obeticholic acid,Pirfenidone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pirfenidone is mainly metabolized by CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the pirfenidone SmPC contraindicates its use in patients with severe hepatic impairment or end-stage liver disease.,(See Summary)
584,Obeticholic acid,Piroxicam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is both a substrate of CYP2C9 and metabolized by hydrolysis. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
585,Obeticholic acid,Pitavastatin,Potential Interaction,NA,"Coadministration has not been studied. Pitavastatin is metabolized by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Obeticholic acid does not interact with these pathways; however, pitavastatin is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. [Note: use of pitavastatin in active liver disease is contraindicated in its US Prescribing Information.]",(See Summary)
586,Obeticholic acid,Pivmecillinam,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Pivmecillinam is hydrolysed to mecillinam, which is excreted primarily in the urine with some biliary excretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
587,Obeticholic acid,Pizotifen,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pizotifen is glucuronidated by UGT2B10, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
588,Obeticholic acid,Posaconazole,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Posaconazole is metabolized via UGTs and is a substrate for P-gp efflux in vitro. It is a potent CYP3A4 inhibitor. Obeticholic acid does not interact with these pathways; however, posaconazole is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
589,Obeticholic acid,Potassium,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Potassium is eliminated renally. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
590,Obeticholic acid,Pramipexole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pramipexole is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OCT2. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
591,Obeticholic acid,Prasugrel,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the prasugrel SmPC contraindicates its use in patients with severe liver impairment.,(See Summary)
592,Obeticholic acid,Pravastatin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pravastatin is not significantly metabolized by cytochrome P450 enzymes. It is a substrate of transport proteins including OAT1B. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
593,Obeticholic acid,Praziquantel,Potential Weak Interaction,NA,"Coadministration has not been studied. In vitro, praziquantel is metabolized predominantly by CYP3A4, which is not affected by obeticholic acid. However, praziquantel is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin.",(See Summary)
594,Obeticholic acid,Prazosin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prazosin undergoes extensive hepatic metabolism primarily by demethylation and conjugation. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
595,Obeticholic acid,Prednicarbate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednicarbate is metabolized to prednisolone-17-ethylcarbonate and then further metabolized to prednisolone. Following topical application, neither prednicarbate nor its metabolites are detected in the systemic circulation. ",(See Summary)
596,Obeticholic acid,Prednisone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolized by CYP3A4 These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
597,Obeticholic acid,Pregabalin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pregabalin is predominantly excreted unchanged in the urine by glomerular filtration and undergoes negligible metabolism. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
598,Obeticholic acid,Primaquine,Potential Weak Interaction,NA,"Coadministration has not been studied. Primaquine is metabolized mainly through a non-CYP mediated mechanism and only a small fraction of the drug is believed to be metabolized through CYP450. However, primaquine is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
599,Obeticholic acid,Primidone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Primidone is a substrate and inducer of CYP3A4. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
600,Obeticholic acid,Prochlorperazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is primarily metabolized by CYP2D6 and CYP2C19, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
601,Obeticholic acid,Proguanil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Proguanil is partly excreted unchanged and partly metabolized to its more active metabolite cycloguanil by CYP2C19 and to a lesser extent by CYP3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
602,Obeticholic acid,Promethazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolized by CYP2D6, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
603,Obeticholic acid,Propafenone,Potential Interaction,NA,Coadministration has not been studied. Propafenone is mainly metabolized by CYP2D6 and to a lesser extent CYP3A4 and CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates. Closely monitor patient response and adjust the dose of propafenone if required. Obeticholic acid has no effect on CYP2D6 or CYP3A4. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ,(See Summary)
604,Obeticholic acid,Propofol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propofol is glucuronidated by UGTs 1A9 and 1A8 and is oxidised to a limited extent by CYP2B6. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
605,Obeticholic acid,Propranolol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolized by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation). Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
606,Obeticholic acid,Protamine sulphate,No Interaction Expected,NA,"Coadministration has not been studied but based on very limited data concerning the metabolism, elimination, and toxicity profiles of protamine an interaction would appear unlikely. Protamine complexed with heparin is thought to be metabolized by fibrinolysin and no CYP metabolism has been described. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
607,Obeticholic acid,Prucalopride,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolized and mainly eliminated renally, partly by active secretion by renal transporters. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
608,Obeticholic acid,Pseudoephedrine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pseudoephedrine is minimally metabolized by MAOs and ~70% is excreted unchanged in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
609,Obeticholic acid,Pyrantel,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrantel is metabolized by CYP2D6 but only a very small proportion of pyrantel is absorbed from the gastrointestinal tract and therefore there is limited potential for interactions. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
610,Obeticholic acid,Pyrazinamide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrazinamide is metabolized by xanthine oxidase, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
611,Obeticholic acid,Pyridostigmine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyridostigmine is predominantly eliminated unchanged via renal tubular secretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
612,Obeticholic acid,Pyrimethamine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Data on the exact pathways of metabolism of pyrimethamine are limited but few interactions have been described with this drug. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
613,Obeticholic acid,Quazepam,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quazepam is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
614,Obeticholic acid,Quetiapine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quetiapine is predominantly metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
615,Obeticholic acid,Quinapril,Potential Weak Interaction,NA,"Coadministration has not been studied. Following absorption, quinapril is de-esterified to its major active metabolite, quinaprilat, which is eliminated primarily by renal excretion via OAT3. Obeticholic acid does not interact with this pathway; however, quinapril is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin.",(See Summary)
616,Obeticholic acid,Quinidine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinidine is a substrate of CYP3A4 and P-gp. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
617,Obeticholic acid,Quinine,No Interaction Expected,NA,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Quinine is extensively metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
618,Obeticholic acid,Rabeprazole,Potential Weak Interaction,NA,"Coadministration has not been studied. Rabeprazole is mainly metabolized by CYP2C19 and CYP3A4, which are not affected by obeticholic acid; however, rabeprazole is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
619,Obeticholic acid,Raloxifene,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Raloxifene is metabolized by UGTs, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the raloxifene SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
620,Obeticholic acid,Raltegravir,No Interaction Expected,NA,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Raltegravir is metabolized by UGT1A1, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
621,Obeticholic acid,Ramipril,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is metabolized by esterases and glucuronidation. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
622,Obeticholic acid,Ranitidine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranitidine is not extensively metabolized and is eliminated primarily by renal excretion. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
623,Obeticholic acid,Ranolazine,Potential Weak Interaction,NA,"Coadministration has not been studied. Ranolazine is primarily metabolized by CYP3A4, which is not affected by obeticholic acid; however, ranolazine is a weak BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. Consider monitoring serum transaminases and bilirubin. Note: the ranolazine SmPC contraindicates its use in patients with moderate to severe hepatic impairment.",(See Summary)
624,Obeticholic acid,Rasagiline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rasagiline is metabolized predominantly by CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the rasagiline SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
625,Obeticholic acid,Repaglinide,Potential Weak Interaction,NA,"Coadministration has not been studied. Repaglinide is metabolized mainly by CYP2C8 with CYP3A4 playing a minor role and is a substrate of OATP1B1. Obeticholic acid does not interact with these pathways; however, repaglinide is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
626,Obeticholic acid,Retigabine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is no evidence for the hepatic oxidative metabolism of retigabine or its metabolites by cytochrome P450 enzymes. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
627,Obeticholic acid,Retinol (Vitamin A),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. Retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
628,Obeticholic acid,Ribavirin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ribavirin is partly metabolized (non-CYP-mediated) and partly excreted in the urine. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
629,Obeticholic acid,Riboflavin (Vitamin B2),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as riboflavin does not undergo CYP metabolism and is primarily eliminated in urine.,(See Summary)
630,Obeticholic acid,Rifabutin,Potential Weak Interaction,NA,"Coadministration has not been studied. Rifabutin is mainly metabolized by CYP3A4 and cholinesterase. Obeticholic acid does not interact with these pathways. Rifabutin is an inducer of CYPs 3A4, 2B6, 2C8, and P-gp and a weak inhibitor of BSEP in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
631,Obeticholic acid,Rifampicin,Potential Weak Interaction,NA,"Coadministration has not been studied. Rifampicin is a potent inducer of cytochrome P450 isoenzymes, including CYP3A4, and P-gp. Obeticholic acid does not interact with these pathways; however, rifampicin is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
632,Obeticholic acid,Rifapentine,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Rifapentine is an inducer of CYP3A4 and CYP2C8/9. Obeticholic acid does not interact with these pathways; however, rifapentine is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
633,Obeticholic acid,Rifaximin,Potential Weak Interaction,NA,"Coadministration has not been studied. Rifaximin is mainly excreted in faeces, almost entirely as unchanged drug. Rifaximin is a substrate of P-gp, a weak inducer of CYP3A4 and an inhibitor of P-gp. Obeticholic acid does not interact with these pathways; however, rifaximin is a BSEP inhibitor in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. [Note: caution should be exercised when rifaximin is administered to patients with severe hepatic impairment, as whilst a clinically significant induction is unlikely at normal doses, the effect of higher concentrations of rifaximin in patients with hepatic impairment is unknown. Obeticholic acid should be prescribed at a dose of 5 mg WEEKLY and titrated to a maximum dose of 10 mg twice a WEEK in patients with Childs Pugh B and C liver disease.]",(See Summary)
634,Obeticholic acid,Rilmenidine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rilmenidine is not metabolized to any great extent. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
635,Obeticholic acid,Rilpivirine,No Interaction Expected,NA,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Rilpivirine is metabolized primarily by CYP3A, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
636,Obeticholic acid,Rilpivirine/ Emtricitabine/Tenofovir alafenamide (RPV/FTC/TAF),No Interaction Expected,NA,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Rilpivirine is metabolized primarily by CYP3A; emtricitabine and tenofovir alafenamide are eliminated renally. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
637,Obeticholic acid,Rimantadine,No Interaction Expected,NA,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Rimantadine undergoes complex liver metabolism being both hydroxylated and glucuronidated. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
638,Obeticholic acid,Riociguat,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Riociguat is metabolized by CYP1A1, CYP3A4, CYP2C8, and CYP2J2 and also eliminated unchanged in the bile and renally. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the riociguat SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
639,Obeticholic acid,Risedronate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is no evidence of systemic metabolism of risedronate; 60% of the dose is distributed to bone and the remainder is excreted in the urine. However, the absorption of risedronate may be affected by food, drinks (other than plain water), or other medicinal products. Risedronate should be taken at least 2 hours before and at least 2 hours after any food, medicinal product, or drink. [Note: this interaction is not specific for obeticholic acid, but for any medication taken with risedronate.]",(See Summary)
640,Obeticholic acid,Risperidone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Risperidone undergoes metabolism by CYP2D6 and CYP3A4, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
641,Obeticholic acid,Ritonavir,Potential Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ritonavir is extensively metabolized by CYP3A4, and to a lesser extent CYP2D6, which are not affected by obeticholic acid; however, ritonavir is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: the ritonavir SmPC contraindicates its use in patients with decompensated liver disease.",(See Summary)
642,Obeticholic acid,Rituximab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rituximab is removed by opsonization via the reticuloendothelial system. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
643,Obeticholic acid,Rivaroxaban,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rivaroxaban is metabolized via CYP3A4, CYP2J2 and CYP-independent mechanisms. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces. Note: the rivaroxaban SmPC contraindicates its use in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C.",(See Summary)
644,Obeticholic acid,Rizatriptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as rizatriptan is metabolized by MAO. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the rizatriptan SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
645,Obeticholic acid,Ropinirole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ropinirole is metabolized predominantly by CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the ropinirole SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
646,Obeticholic acid,Rosiglitazone,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Rosiglitazone is metabolized mainly by CYP2C8 and to a lesser extent by CYP2C9. Obeticholic acid does not interact with these pathways; however, rosiglitazone is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
647,Obeticholic acid,Rosuvastatin,No Interaction Expected,NA,"Coadministration of 20 mg of rosuvastatin with 10 mg of obeticholic acid increased rosuvastatin AUC and Cmax by 22% and 27%, respectively. These increases are not clinically relevant. Rosuvastatin is a substrate for OATP1B1 and BCRP. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.","No clinically relevant interactions were seen when the following drugs were administered as single doses concomitantly with Ocaliva 10 mg once daily: Rosuvastatin 20 mg (BCRP, OATP1B1, OATP1B3 substrate): 22% increase in AUC and a 27% increase in Cmax of rosuvastatin.Ocaliva Prescribing Information, Intercept Pharmaceuticals Inc., January 2018.Coadministration of rosuvastatin (20 mg, single dose) with obeticholic acid (10 or 25 mg, once daily) was studied in 48 healthy volunteers in a crossover trial. Rosuvastatin AUC and Cmax increased by 22% and 27%, respectively, when given with the 10 mg dose of obeticholic acid. With the 25 mg dose of obeticholic acid, rosuvastatin AUC and Cmax increased by 30% and 26%, respectively. As the increases were not dose-related, it was concluded that rosuvastatin had no clinically relevant effect on BCRP/OATP1B1/B3, which transport rosuvastatin.Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Edwards JE, Eliot L, Parkinson A, et al. Adv Ther. 2017, 34(9): 2120–2138."
648,Obeticholic acid,Rufinamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rufinamide is metabolized mainly by hydrolysis. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
649,Obeticholic acid,Salbutamol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolized to the inactive salbutamol-4’-O-sulphate. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
650,Obeticholic acid,Salmeterol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
651,Obeticholic acid,Saquinavir,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Saquinavir is metabolized by CYP3A4, which is not affected by obeticholic acid; however, saquinavir and coprescribed ritonavir are BSEP inhibitors. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. ",(See Summary)
652,Obeticholic acid,Saxagliptin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolized by CYP3A4/5, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
653,Obeticholic acid,Selexipag,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Selexipag is hydrolysed to its active metabolite by carboxylesterase 1 (CES1). Both selexipag and its active metabolite undergo oxidative metabolism by CYP2C8 and CYP3A4. The active metabolite is also glucuronidated by UGT1A3 and UGT2B7. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
654,Obeticholic acid,Senna,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces and in other secretions. No clinically significant drug interactions are known.,(See Summary)
655,Obeticholic acid,Serenoa repens,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
656,Obeticholic acid,Sertraline,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolized by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6, and 3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: use with caution in patients with hepatic impairment when a lower or less frequent dose may be required. Sertraline should not be used in patients with severe hepatic impairment.]",(See Summary)
657,Obeticholic acid,Sevelamer,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sevelamer works locally in the GI tract as a phosphate binder with no systemic absorption. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
658,Obeticholic acid,Sildenafil (erectile dysfunction),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the sildenafil SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
659,Obeticholic acid,Sildenafil (pulmonary arterial hypertension),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the sildenafil SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
660,Obeticholic acid,Silodosin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Silodosin is a substrate of CYP3A4 and P-gp. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the silodosin SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
661,Obeticholic acid,Simeprevir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simeprevir is metabolized by CYP3A4. Obeticholic acid does not interact with CYP3A4. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
662,Obeticholic acid,Simeticone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simeticone is not absorbed from the gastrointestinal tract.,(See Summary)
663,Obeticholic acid,Simvastatin,Potential Interaction,NA,"Coadministration has not been studied. Simvastatin is metabolized by CYP3A4, which is not affected by obeticholic acid; however, simvastatin is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
664,Obeticholic acid,Sirolimus,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sirolimus is a substrate of CYP3A4 and P-gp, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
665,Obeticholic acid,Sitagliptin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is mainly eliminated unchanged and only metabolized to a small extent (~20%) by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
666,Obeticholic acid,Sodium stibogluconate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Elimination of sodium stibogluconate is predominantly by renal glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
667,Obeticholic acid,Sofosbuvir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sofosbuvir is a prodrug and formation of its active metabolite is unlikely to be affected by comedications. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
668,Obeticholic acid,Sofosbuvir/Velpatasvir,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sofosbuvir and velpatasvir are substrates of P-gp and BCRP. Velpatasvir is also a substrate of OATP1B and CYP2B6, 2C8 and 3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
669,Obeticholic acid,Sofosbuvir/Velpatasvir/Voxilaprevir,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sofosbuvir, velpatasvir, and voxilaprevir are substrates of P-gp and BCRP. Velpatasvir and voxilaprevir are also substrates of OATP1B. In vitro, slow metabolic turnover of velpatasvir primarily by CYP2B6, CYP2C8, and CYP3A4 and of voxilaprevir primarily by CYP3A4 was observed. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
670,Obeticholic acid,Solifenacin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Solifenacin is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the solifenacin SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
671,Obeticholic acid,Sorafenib,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sorafenib is metabolized to a moderate extent by CYP3A4 and UGT1A9, UGT1A1. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
672,Obeticholic acid,Sotalol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sotalol is mainly excreted in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ,(See Summary)
673,Obeticholic acid,Spectinomycin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spectinomycin is predominantly eliminated unchanged by the kidneys via glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
674,Obeticholic acid,Spironolactone,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Spironolactone is partly metabolized by the flavin-containing monooxygenases and is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. ",(See Summary)
675,Obeticholic acid,Stavudine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Stavudine is excreted renally. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ,(See Summary)
676,Obeticholic acid,St John's wort,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. St John’s wort is a CYP3A4 inducer. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
677,Obeticholic acid,Streptokinase,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other proteins, streptokinase is metabolized proteolytically in the liver and eliminated via the kidneys. Renal elimination of unchanged streptokinase is minimal. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
678,Obeticholic acid,Streptomycin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Streptomycin is excreted rapidly in the urine by glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
679,Obeticholic acid,Strontium ranelate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Strontium is not metabolized and is excreted unchanged by the kidneys. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
680,Obeticholic acid,Sulfadiazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sulfadiazine is partly metabolized by CYP2C9, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the sulfadiazine SmPC contraindicates its use in patients with severe liver impairment.",(See Summary)
681,Obeticholic acid,Sulfadoxine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sulfadoxine is rarely used alone but is usually given in combination with pyrimethamine. Sulfadoxine is partly metabolized by CYP2C9, which is not affected by obeticholic acid. Data on the exact pathways of metabolism of pyrimethamine are limited but few interactions have been described with this drug. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces. ",(See Summary)
682,Obeticholic acid,Sulfasalazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Multiple mechanisms are thought to be involved in sulfasalazine metabolism including acetylation, hydroxylation, and glucuronidation. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
683,Obeticholic acid,Sulpiride,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant is unlikely. Sulpiride is mainly excreted in the urine and faeces as unchanged drug. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
684,Obeticholic acid,Sultiame,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Limited data suggest that sultiame is a substrate and inhibitor of CYP3A4. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
685,Obeticholic acid,Sumatriptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sumatriptan is eliminated primarily by metabolism mediated by monoamine oxidase A. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the sumatriptan SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
686,Obeticholic acid,Sunitinib,Potential Weak Interaction,NA,"Coadministration has not been studied. Sunitinib is metabolized by CYP3A4, which is not affected by obeticholic acid; however, sunitinib is a weak inhibitor of BSEP in vitro. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin.",(See Summary)
687,Obeticholic acid,Tacrolimus,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Tacrolimus is metabolized by CYP3A4, which is not affected by obeticholic acid; however, tacrolimus is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
688,Obeticholic acid,Tadalafil (erectile dysfunction),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ",(See Summary)
689,Obeticholic acid,Tadalafil (pulmonary arterial hypertension),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
690,Obeticholic acid,Tamoxifen,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tamoxifen metabolism occurs mostly via two pathways: the formation of N-desmethyltamoxifen (via mainly CYP3A4 and CYP3A5) is the main route (92%) and the formation of 4-hydroxytamoxifen (via CYP2D6 > 2C9/19, CYP3A4 and CYP2B6) is a minor route (7%). Further metabolism of both metabolites results in the formation of endoxifen, which is thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen. Endoxifen is formed from N-desmethyltamoxifen via CYP2D6 and from 4-hydroxytamoxifen via CYP3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: tamoxifen has been associated uncommonly with cirrhosis and rarely with hepatitis, cholestasis, hepatic failure, hepatocellular injury, and hepatic necrosis. Coadminister with care as obeticholic acid may also cause drug-induced liver injury.",(See Summary)
691,Obeticholic acid,Tamsulosin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the tamsulosin SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
692,Obeticholic acid,Tapentadol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tapentadol undergoes complex metabolic pathways including glucuronidation followed by some minimal metabolism by CYPs 2C9, 2C19, and 2D6. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
693,Obeticholic acid,Tazobactam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tazobactam is only minimally metabolized and is eliminated primarily by renal excretion via OAT1/3. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
694,Obeticholic acid,Telbivudine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telbivudine is eliminated primarily via urinary excretion of the unchanged drug by passive diffusion, so interaction via this pathway is unlikely. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
695,Obeticholic acid,Telithromycin,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Telithromycin is a substrate and inhibitor of CYP3A4, P-gp and OAT1B1 and inhibitor of CYP3A4 and P-gp. Obeticholic acid does not interact with these pathways; however, telithromycin is BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. ",(See Summary)
696,Obeticholic acid,Telmisartan,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Telmisartan is largely glucuronidated by UGT1A3, which is not affected by obeticholic acid; however, telmisartan is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
697,Obeticholic acid,Temazepam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temazepam is metabolized by glucuronidation and sulfation and these pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the temazepam SmPC contraindicates its use in patients with severe hepatic impairment,(See Summary)
698,Obeticholic acid,Temocillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as temocillin is excreted unchanged in the urine. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ,(See Summary)
699,Obeticholic acid,Temsirolimus,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Temsirolimus is metabolized by CYP3A4, which is not affected by obeticholic acid; however, temsirolimus is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
700,Obeticholic acid,Tenofovir alafenamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tenofovir alafenamide is metabolized to tenofovir (major metabolite) by carboxylesterase-1 and cathepsin A. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
701,Obeticholic acid,Tenofovir-DF (HBV),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tenofovir-DF is cleared renally by OAT1/3. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
702,Obeticholic acid,Tenofovir-DF (HIV),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tenofovir-DF is excreted renally. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
703,Obeticholic acid,Terbinafine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terbinafine is metabolized by CYP1A2, 2C9, 3A4 and to a lesser extent CYP2C8 and 2C19. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: terbinafine in patients with chronic or active liver disease has not been studied in prospective clinical trials and therefore cannot be recommended for such patients. The terbinafine SmPC contraindicates its use in patients with severe liver impairment.]",(See Summary)
704,Obeticholic acid,Terfenadine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terfenadine undergoes extensive metabolism mainly by CYP3A4 to form azacyclonol and terfenadine alcohol. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
705,Obeticholic acid,Tetracyclines,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tetracyclines are predominantly eliminated unchanged by the kidneys by glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: tetracyclines are contraindicated in chronic hepatic impairment.,(See Summary)
706,Obeticholic acid,Thalidomide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Thalidomide is cleared by non-enzymatic hydrolysis. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
707,Obeticholic acid,Theophylline,Potential Interaction,NA,Coadministration has not been studied. Theophylline is mainly metabolized by CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates. Therapeutic monitoring for theophylline is recommended. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,"Obeticholic acid may increase the exposure to concomitant medicinal products that are CYP1A2 substrates. Therapeutic monitoring of CYP1A2 substrates with narrow therapeutic index (e.g. theophylline) is recommended.Ocaliva SmPC, Intercept Pharma UK & Ireland, March 2018.Obeticholic acid may increase the exposure to concomitant drugs that are CYP1A2 substrates. Therapeutic monitoring of CYP1A2 substrates with a narrow therapeutic index (e.g. theophylline) is recommended when coadministered with obeticholic acid.Ocaliva Prescribing Information, Intercept Pharmaceuticals Inc., January 2018."
708,Obeticholic acid,Thiamine (Vitamin B1),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Thiamine is predominantly eliminated unchanged via the kidneys.,(See Summary)
709,Obeticholic acid,Thiopental,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The isoenzymes involved in thiopental metabolism have not been identified but data from animal studies suggest that enzyme inducers or inhibitors do not modify the duration of surgical anaesthesia or sleep time. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
710,Obeticholic acid,Thioridazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant is unlikely. Thioridazine is metabolized by CYP2D6 and to a lesser extent by CYP3A4, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
711,Obeticholic acid,Tiagabine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiagabine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the tiagabine SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
712,Obeticholic acid,Tianeptine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tianeptine is predominantly metabolized by beta-oxidation and N-demethylation. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
713,Obeticholic acid,Tiapride,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiapride is excreted largely unchanged in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
714,Obeticholic acid,Ticagrelor,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ticagrelor undergoes extensive CYP3A4 metabolism and is a mild inhibitor of CYP3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the ticagrelor SmPC contraindicates its use in patients with severe liver impairment.,(See Summary)
715,Obeticholic acid,Ticarcillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ticarcillin is eliminated by the kidney and excreted largely unchanged in the urine. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
716,Obeticholic acid,Ticlopidine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ticlopidine is a prodrug that is converted to its active metabolites by CYPs 2C19, 3A4, and 2B6. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
717,Obeticholic acid,Timolol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely when timolol is used either orally or as eye drops. Timolol is predominantly metabolized in the liver by CYP2D6. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: the European SmPC and the US Prescribing Information mention that timolol should be used at a reduced dose in hepatic impairment.],(See Summary)
718,Obeticholic acid,Tinzaparin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tinzaparin is partially metabolized by desulfation and depolymerization and then renally excreted. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
719,Obeticholic acid,Tiotropium,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiotropium bromide is predominantly excreted unchanged in the urine. Metabolism by CYP2D6 and CYP3A4 is only a minor role in its elimination. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
720,Obeticholic acid,Tipranavir,Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Tipranavir is metabolized by CYP3A4, which is not affected by obeticholic acid; however, tipranavir and the ritonavir coprescribed with tipranavir are BSEP inhibitors. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. Note: the tipranavir SmPC contraindicates its use in patients with moderate to severe hepatic impairment.",(See Summary)
721,Obeticholic acid,Tizanidine,Potential Interaction,NA,Coadministration has not been studied. Tizanidine is metabolized by CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates. Therapeutic monitoring of CYP1A2 substrates with a narrow therapeutic index such as tizanidine is recommended. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,"Obeticholic acid may increase the exposure to concomitant medicinal products that are CYP1A2 substrates. Therapeutic monitoring of CYP1A2 substrates with narrow therapeutic index (e.g. tizanidine) is recommended.Ocaliva SmPC, Intercept Pharma UK & Ireland, March 2018.Obeticholic acid may increase the exposure to concomitant drugs that are CYP1A2 substrates. Therapeutic monitoring of CYP1A2 substrates with a narrow therapeutic index (e.g. tizanidine) is recommended when co-administered with Ocaliva.Ocaliva Prescribing Information, Intercept Pharmaceuticals Inc., January 2018."
722,Obeticholic acid,Tolbutamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is mainly metabolized by CYP2C9 and to a lesser extent by CYPs 2C8 and 2C19. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the tolbutamide SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
723,Obeticholic acid,Tolterodine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4 having a major role in CYP2D6 poor metabolizers. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the tolterodine SmPC contraindicates its use in patients with severe hepatic impairment.,(See Summary)
724,Obeticholic acid,Topiramate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Topiramate is mainly eliminated by renal elimination in unchanged form (up to 60% of the dose) and partly by oxidation. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
725,Obeticholic acid,Torasemide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Torasemide is mainly metabolized by CYP2C9, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
726,Obeticholic acid,Tramadol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
727,Obeticholic acid,Trandolapril,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trandolapril is metabolized by esterases to trandolaprilat and then by glucuronidation. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: dose modification may be required in patients with hepatic impairment.,(See Summary)
728,Obeticholic acid,Tranexamic Acid,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tranexamic acid is mainly cleared by glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
729,Obeticholic acid,Trazodone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trazodone is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
730,Obeticholic acid,Treprostinil,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Treprostinil is mainly metabolized by CYP2C8 and to a lesser extent by CYP2C9, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
731,Obeticholic acid,Triamcinolone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triamcinolone is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
732,Obeticholic acid,Triazolam,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triazolam is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
733,Obeticholic acid,Trifluoperazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There are limited data on the metabolism of trifluoperazine, though animal studies have shown little affinity for CYP enzymes. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
734,Obeticholic acid,Trimebutine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimebutine does not appear to be metabolized by CYP enzymes and there are no data on the involvement of transporters.,(See Summary)
735,Obeticholic acid,Trimethoprim/ Sulfamethoxazole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimethoprim is mainly excreted in urine (40-60%) with some evidence that it may be a substrate and inhibitor of CYP2C8. Sulphamethoxazole is mainly excreted in the urine. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
736,Obeticholic acid,Trimipramine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimipramine is metabolized mainly by CYP2D6. Obeticholic acid does not interact with this pathway. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: the European SmPC for trimipramine contraindicates its use in severe liver disease; the US Prescribing Information recommends caution in impaired liver function.],(See Summary)
737,Obeticholic acid,Troleandomycin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Troleandomycin is an inhibitor of CYP3A4 and OATP1B1 and OATP1B3. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
738,Obeticholic acid,Turmeric (curcumin),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Turmeric may inhibit CYP3A4 but this is unlikely to be significant at standard doses. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
739,Obeticholic acid,Ursodeoxycholic acid,No Interaction Expected,NA,Ursodeoxycholic acid can be taken together with obeticholic acid for the treatment of primary biliary cirrhosis. Both obeticholic acid and ursodeoxycholic acid undergo conjugation with glycine and taurine in the liver and are secreted into bile.,(See Summary)
740,Obeticholic acid,Valaciclovir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and elimination a clinically significant interaction is unlikely. Valaciclovir is a substrate for OAT3 and is eliminated renally (as aciclovir) by glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
741,Obeticholic acid,Valerian,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
742,Obeticholic acid,Valproate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproate is mainly glucuronidated by UGTs 1A6, 1A9, and 2B7 and metabolized by CYP2C9 and CYP2C19. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. The intestinal microbiota deconjugates obeticholic acid, leading to reabsorption or excretion in the faeces.",(See Summary)
743,Obeticholic acid,Valsartan,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valsartan is not significantly metabolized and is excreted mainly via the bile as unchanged drug. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the valsartan SmPC contraindicates its use in patients with severe hepatic impairment, biliary cirrhosis, or cholestasis. The SmPC for valsartan states a maximum dose of 80 mg in mild to moderate hepatic impairment, but the US Prescribing Information states no dosage requirement in this level of impairment.",(See Summary)
744,Obeticholic acid,Vancomycin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vancomycin is excreted unchanged via renal glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
745,Obeticholic acid,Vardenafil,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vardenafil is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the vardenafil SmPC contraindicates its use in patients with severe hepatic impairment.",(See Summary)
746,Obeticholic acid,Varenicline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Less than 10% of varenicline is metabolized and it is predominantly eliminated unchanged by the kidneys. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
747,Obeticholic acid,Venlafaxine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Venlafaxine is mainly metabolized by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19, and 2C9. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
748,Obeticholic acid,Verapamil,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Verapamil is metabolized by multiple CYPs, mainly CYP3A4 but also CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
749,Obeticholic acid,Vernakalant,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vernakalant is metabolized by CYP2D6 and UGTs. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
750,Obeticholic acid,Vigabatrin,No Interaction Expected,NA,Coadministration has not been studied but a clinically significant interaction is unlikely as vigabatrin is not metabolized and is cleared mainly by glomerular filtration. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
751,Obeticholic acid,Vildagliptin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vildagliptin is inactivated via non-CYP mediated hydrolysis. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
752,Obeticholic acid,Vinblastine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vinblastine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
753,Obeticholic acid,Vincristine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vincristine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
754,Obeticholic acid,Vinorelbine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vinorelbine is metabolized by CYP3A4, which is not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the vinorelbine SmPC contraindicates its use in patients with severe hepatic impairment. ",(See Summary)
755,Obeticholic acid,Vitamin E,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vitamin E is minimally metabolized by the liver.,(See Summary)
756,Obeticholic acid,Voriconazole,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Voriconazole is a strong inhibitor of CYP3A4 and is metabolized by CYPs 2C19, 2C9, and 3A4. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
757,Obeticholic acid,Vortioxetine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vortioxetine is primarily metabolized by CYP2D6, with minor involvement from CYP3A4. Obeticholic acid has no effect on CYP2D6 or CYP3A4. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
758,Obeticholic acid,Warfarin,Potential Interaction,NA,"Coadministration of warfarin (25 mg) with obeticholic acid (10 mg) increased S-warfarin AUC and Cmax by 13 and 12%, respectively, and R-warfarin AUC and Cmax by 20% and 11%, respectively. This resulted in an IRN decrease of 11%. Monitor INR and adjust the dose of warfarin if needed. Warfarin is a mixture of enantiomers, which are metabolized by different cytochromes. R-warfarin is primarily metabolized by CYPs 1A2 and 3A4 whereas S-warfarin (more potent) is metabolized by CYP2C9. Obeticholic acid may increase the exposure of CYP1A2 substrates. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.","International normalised ratio (INR) is decreased following co-administration of warfarin and obeticholic acid. INR should be monitored and the dose of warfarin adjusted, if needed, to maintain the target INR range when co-administering obeticholic acid and warfarin.Ocaliva SmPC, Intercept Pharma UK & Ireland, March 2018.The International Normalized Ratio (INR) decreased following coadministration of warfarin and Ocaliva. Monitor INR and adjust the dosage of warfarin, as needed, to maintain the target INR range when co-administering Ocaliva and warfarin. Concomitant administration of 25 mg warfarin as a single dose with Ocaliva 10 mg once daily resulted in 13% increase in systemic exposure to S-warfarin and 11% decrease in maximum INR.Ocaliva Prescribing Information, Intercept Pharmaceuticals Inc., January 2018.Coadministration of warfarin (25 mg, single dose) and obeticholic acid (10 and 25 mg, once daily) was studied in 48 healthy volunteers in a crossover trial. S-warfarin AUC and Cmax increased by 13% and 12%, respectively. R-warfarin AUC and Cmax increased by 20% and 11%, respectively. The IRN fell by 11% when coadministered with 10 mg obeticholic acid and by 7% when coadministered with 25 mg obeticholic acid.Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Edwards JE, Eliot L, Parkinson A, et al. Adv Ther. 2017, 34(9): 2120–2138."
759,Obeticholic acid,Xipamide,No Interaction Expected,NA,"Coadministration has not been studied, based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 90% of xipamide is excreted in the urine, mainly as unchanged drug (~50%) and glucuronides (30%). Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
760,Obeticholic acid,Zaleplon,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zaleplon is mainly metabolized by aldehyde oxidase and to a lesser extent CYP3A4. These pathways are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
761,Obeticholic acid,Zanamivir,No Interaction Expected,NA,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Zanamivir is not extensively metabolized and only a small amount of the orally inhaled drug is systematically absorbed. Absorbed zanamivir is excreted unchanged in the urine whereas unabsorbed zanamivir is excreted in the faeces. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ,(See Summary)
762,Obeticholic acid,Zidovudine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Zidovudine is metabolized by UGTs. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. ,(See Summary)
763,Obeticholic acid,Ziprasidone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately two-thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
764,Obeticholic acid,Zofenopril,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zofenopril is a prodrug metabolized in the liver by a non-CYP mechanism to zofenoprilat, the active metabolite. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
765,Obeticholic acid,Zolmitriptan,Potential Interaction,NA,Coadministration has not been studied. Zolmitriptan metabolism is complex with CYP1A2 involvement. Obeticholic acid may increase the exposure of CYP1A2 substrates. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. A maximum dose of 5 mg zolmitriptan in 24 hours is recommended in patients taking specific inhibitors of CYP1A2,(See Summary)
766,Obeticholic acid,Zolpidem,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP1A2. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the zolpidem SmPC contraindicates its use in patients with severe hepatic impairment,(See Summary)
767,Obeticholic acid,Zonisamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zonisamide is metabolized by CYP3A4 and by N-acetyl-transferases and conjugation. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.,(See Summary)
768,Obeticholic acid,Zopiclone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C8, which are not affected by obeticholic acid. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. [Note: elimination of zopiclone may be reduced in patients with hepatic dysfunction and a lower dose of zopiclone nightly is recommended for these patients. Zopiclone is contraindicated in patients with severe hepatic insufficiency.]",(See Summary)
769,Obeticholic acid,Zuclopentixol,No Interaction Expected,NA,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant is unlikely. Zuclopenthixol is metabolized by sulphoxidation, N-dealkylation (by CYP2D6 and CYP3A4) and glucuronidation. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile.",(See Summary)
770,Obeticholic acid,Drospirenone/estradiol (HRT),Potential Interaction,NA,"Coadministration has not been studied but is not recommended. Estradiol is metabolized by CYP3A4 and CYP1A2 and is glucuronidated. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Drospirenone is metabolised in part by CYP3A4, which is not affected by obeticholic acid; however, drospirenone is a BSEP inhibitor. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
771,Obeticholic acid,Desogestrel/ethinylestradiol (COC),Potential Interaction,NA,"Coadministration has not been studied but is not recommended. Ethinylestradiol is mainly metabolized by hydroxylation with CYP3A4 and CYP2C9. Desogestrel is a prodrug that requires activation to etonogestrel by CYP2C9 (and possibly CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4. These pathways are not affected by obeticholic acid; however, ethinylestradiol is a BSEP inhibitor. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. ",(See Summary)
772,Obeticholic acid,Dydrogesterone/estradiol (HRT) ,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolized by CYP3A4 and CYP1A2 and is glucuronidated. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Dydrogesterone is metabolized to dihydrodydrogesterone (possibly via CYP3A4), which is not affected by obeticholic acid.",(See Summary)
773,Obeticholic acid,Medroxyprogesterone (oncology),Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Medroxyprogesterone is metabolized by CYP3A4, which is not affected by obeticholic acid; however, medroxyprogesterone is a BSEP inhibitor. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Coadministration with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
774,Obeticholic acid,Gestodene/ethinylestradiol (COC),Potential Interaction,NA,"Coadministration has not been studied and is not recommended. Ethinylestradiol is mainly metabolized by hydroxylation with CYP3A4 and CYP2C9. Gestodene is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. These pathways are not affected by obeticholic acid; however, ethinylestradiol is a BSEP inhibitor. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. ",(See Summary)
775,Obeticholic acid,Medroxyprogesterone/conjugated estrogens (HRT),Potential Interaction,NA,"Coadministration has not been studied but is not recommended. Medroxyprogesterone is metabolized by CYP3A4. The metabolism of conjugated estrogens is complex and involves CYP3A4 isoenzymes and glucuronidation in the liver. These pathways are not affected by obeticholic acid; however, medroxyprogesterone is a BSEP inhibitor. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. ",(See Summary)
776,Obeticholic acid,Norethisterone (Norethindrone) (POP),Potential Weak Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely and contraceptive efficacy is unlikely to be affected. Norethisterone is metabolized by CYP3A4, which is not affected by obeticholic acid. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. However, norethisterone is only a weak BSEP inhibitor in vitro and a clinically significant interaction is unlikely. Consider additional monitoring of serum transaminases and bilirubin if clinical symptoms occur.",(See Summary)
777,Obeticholic acid,Norelgestromin/ethinylestradiol (patch),Potential Interaction,NA,"Coadministration with this combination has not been studied and is not recommended. Ethinylestradiol is mainly metabolized by hydroxylation with CYP3A4 and CYP2C9. Norelgestromin is metabolized to norgestrel (possibly by CYP3A4). These pathways are not affected by obeticholic acid; however, ethinylestradiol is a BSEP inhibitor. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. ",(See Summary)
778,Obeticholic acid,Norethisterone (Norethindrone)/ethinylestradiol (COC),Potential Interaction,NA,"Coadministration with this combination has not been studied and is not recommended. Norelgestromin is metabolized to norgestrel (possibly by CYP3A4). Norethisterone is metabolized by CYP3A4. Ethinylestradiol is mainly metabolized by hydroxylation with CYP3A4 and CYP2C9. These pathways are not affected by obeticholic acid; however, ethinylestradiol and norethisterone are BSEP inhibitors. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. ",(See Summary)
779,Obeticholic acid,Norgestimate/ethinylestradiol (COC),Potential Interaction,NA,"Coadministration has not been studied but is not recommended. Norgestimate is deacetylated to the active metabolite norelgestromin, which is then possibly metabolized by CYP3A4 to norgestrel. Ethinylestradiol is mainly metabolized by hydroxylation with CYP3A4 and CYP2C9. These pathways are not affected by obeticholic acid; however, ethinylestradiol is a BSEP inhibitor. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. ",(See Summary)
780,Obeticholic acid,Norethisterone (Norethindrone)/mestranol (COC) ,Potential Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely and contraceptive efficacy is unlikely to be affected. Norethisterone is metabolized by CYP3A4. Mestranol is rapidly and almost completely converted to ethinylestradiol by CYP2C9. These pathways are not affected by obeticholic acid; however, ethinylestradiol  and norethisterone are BSEP inhibitors. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
781,Obeticholic acid,Norethisterone (Norethindrone) (depot injection),Potential Weak Interaction,NA,"Coadministration with norethisterone as a depot injection has not been studied but based on metabolism and clearance a clinically significant interaction is not anticipated and contraceptive efficacy is unlikely to be affected. Norethisterone is metabolised by CYP3A4, which is not affected by obeticholic acid. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. However, norethisterone is only a weak BSEP inhibitor in vitro and a clinically significant interaction is unlikely. Consider additional monitoring of serum transaminases and bilirubin if clinical symptoms occur.",(See Summary)
782,Obeticholic acid,Norethisterone (Norethindrone)/estradiol (HRT),Potential Weak Interaction,NA,"Coadministration has not been studied. Estradiol is metabolized by CYP3A4 and CYP1A2 and is glucuronidated. Obeticholic acid may increase the exposure of CYP1A2 substrates but this is unlikely to be clinically relevant. Norethisterone is metabolised by CYP3A4. These pathways are not affected by obeticholic acid. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. However, norethisterone is only a weak BSEP inhibitor in vitro and a clinically significant interaction is unlikely. Consider additional monitoring of serum transaminases and bilirubin if clinical symptoms occur.",(See Summary)
783,Obeticholic acid,Norgestrel/ethinylestradiol (COC),Potential Interaction,NA,"Coadministration has not been studied but is not recommended. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Ethinylestradiol is mainly metabolized by hydroxylation with CYP3A4 and CYP2C9. These pathways are not affected by obeticholic acid; however, ethinylestradiol is a BSEP inhibitor. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. ",(See Summary)
784,Obeticholic acid,Conjugated estrogens (HRT),Potential Interaction,NA,"Coadministration has not been studied but is not recommended. The metabolism of conjugated estrogens is complex and involves CYP3A4 isoenzymes and glucuronidation in the liver. These pathways are not affected by obeticholic acid; however, medroxyprogesterone is a BSEP inhibitor. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. ",(See Summary)
785,Obeticholic acid,Norgestrel/conjugated estrogens (HRT),Potential Interaction,NA,"Coadministration has not been studied but is not recommended. The metabolism of conjugated estrogens is complex and involves CYP3A4 isoenzymes and glucuronidation in the liver. These pathways are not affected by obeticholic acid; however, medroxyprogesterone is a BSEP inhibitor. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. ",(See Summary)
786,Obeticholic acid,Influenza vaccine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is some evidence that vaccines may downregulate CYP3A4, but obeticholic acid does not interact with this pathway.",(See Summary)
787,Obeticholic acid,Adalimumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Adalimumab is a monoclonal IgG antibody. Elimination is similar to endogenous IgG and occurs primarily via proteolytic catabolism throughout the body. Obeticholic acid is not expected to interact with this pathway.,(See Summary)
788,Obeticholic acid,Mesna,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. In vitro data suggest that mesna is a substrate of the OAT1, OAT3 and OAT4 renal transporters. Obeticholic acid does not interact with these pathways.",(See Summary)
789,Obeticholic acid,Cyclophosphamide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyclophosphamide is activated (major pathway) to 4-hydroxycyclophosphamide by CYPs 2B6 (major), 2C9 and 3A4. Inactivation (minor, 10%) to the neurotoxic chloroacetaldehyde metabolite is performed mainly by CYP3A4. Obeticholic acid does not interact with these pathways. ",(See Summary)
790,Obeticholic acid,Medroxyprogesterone/estradiol (HRT),Potential Interaction,NA,"Coadministration has not been studied but is not recommended. Estradiol is metabolized by CYP3A4 and CYP1A2 and is glucuronidated. Medroxyprogesterone is metabolized by CYP3A4. These pathways are not affected by obeticholic acid; however, drospirenone is a BSEP inhibitor. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment.",(See Summary)
791,Obeticholic acid,Procyclidine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Little is known about procyclidine metabolism but it is likely to be metabolised by P450 and glucuronidated. Obeticholic acid does not interact with these pathways.,(See Summary)
792,Obeticholic acid,Alcohol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase. Acute alcohol use inhibits CYP2E1. Chronic use may induce CYP2E1 and to a lesser extent CYP3A4 but this is unlikely to be clinically relevant. Obeticholic acid does not interact with these pathways.,(See Summary)
793,Obeticholic acid,Cannabidiol (CBD),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cannabidiol is mainly metabolized by CYP3A4 and CYP2C19. Obeticholic acid does not interact with these pathways.,(See Summary)
794,Obeticholic acid,Clofazimine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofazimine is largely excreted unchanged in the faeces, both as unabsorbed drug and via biliary excretion. Obeticholic acid does not affect this pathway. [Note, the US Prescribing Information for clofazimine recommends to avoid clofazimine in patients with hepatic impairment (Child-Pugh Class A, B, and C) unless the benefit outweighs the risk.]",(See Summary)
795,Obeticholic acid,Carfentanil,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Carfentanil is expected to be metabolized by CYP3A4/5. Obeticholic acid does not interact with this pathway. However, carfentanil is an extremely strong opiate, reported to be up to 10,000 times more potent than morphine, and multiple deaths have resulted from its use. Advise patients to avoid.",(See Summary)
796,Obeticholic acid,Drospirenone/ethinylestradiol (COC),Potential Interaction,NA,"Coadministration has not been studied but is not recommended. Ethinylestradiol is mainly metabolized by hydroxylation with CYP3A4 and CYP2C9. Drospirenone is metabolised in part by CYP3A4. These pathways are not affected by obeticholic acid; however, both drospirenone and ethinylestradiol are BSEP inhibitors. Coadministration of obeticholic acid with a BSEP inhibitor can lead to build up of conjugated bile salts and result in clinical symptoms. If coadministration is necessary, monitor serum transaminases and bilirubin. Consider dose modification, especially in patients with liver impairment. ",(See Summary)
